Stock Movers

AB Foods Under Pressure Following Profit Warning

"Now we've had a number of reports out for UK businesses; there's a profit warning too from AB foods today. AB food shares are down quite a lot this morning on the back of that profit warning. AB Foods consists of Primark and a range of food businesses including brands like Ravita Crackers and Kings Meal Bread. It was noted that while Primark is struggling in continental Europe and the US, it is doing a little better in the UK. The profit warning comes at a pivotal time as the company is considering splitting Primark from the rest of the business, with a decision expected by April."

The discussion on AB Foods centers on a profit warning that has led to a sharp decline in its share price. The report emphasizes the struggles of Primark internationally and notes an upcoming decision regarding the potential split of Primark from the rest of the company, signaling near-term uncertainty and bearish sentiment.

Adecco Faces Downside Amid Tight Labor Market

"The Swiss French recruitment company, Adeco, is facing a drop this morning. What does that tell us about the broader labor market trends? >> Well, the business of recruitment isn't the best business to be in perhaps at the moment given that we're in quite a tight labor market. Companies are hesitant to spend and candidates are also hesitant to move jobs as well. And so Jeffrey's analyst downgraded three names in that recruitment sector in Europe this morning. So Ranstead, Hayes, and Ado in particular were weaker. Analysts said that these recruiters are facing a really cloudy outlook in 2026 with both cyclical headwinds and new structural challenges."

The insight explains that Adecco, along with its recruitment peers, is under pressure in a tight labor market. Analyst downgrades and a forecast for a cloudy outlook in 2026, driven by cyclical and structural challenges, suggest a bearish sentiment for the company's near-term performance.

BAE Systems Benefits from Potential US Defense Spending Boost

"The defense stock rally here in Europe, BAE Systems, one of the big winners. What is prompting what is a very significant surge? >> Well, it's all about Trump. So, Trump said that he wanted to increase the US military budget and it's not a small boost that he's requesting. He's requesting an increase of more than 50% in annual defense spending for 2027. And he said that that would be paid for by the tariff revenue that was accumulated over the last year. And so, this is something that really boosted Asian defense stocks. And now we are seeing the same with the European names as well. And BAE is really driving that rally."

The commentary highlights that BAE Systems is one of the top performers in the European defense rally, spurred by Trump's proposal to significantly boost US military spending by over 50% for 2027. The speaker notes that tariff revenue will fund this increase, creating a pronounced effect on defense stocks and positioning BAE as a major beneficiary.

Regulatory Pressure on RTX from Trump's Social Media Post

"step up, start investing in more upfront investment like plants and equipment or they will no longer be doing business with the Department of War. And if Rathon wants further business with the United States government, under no circumstances will they be allowed to do additional stock buybacks. This goes on and on."

The excerpt relays a statement, attributed to Trump via social media, targeting RTX (referred to as Rathon) and pressuring the company to increase its capital investments. Failure to do so could jeopardize its future government business, serving as a negative catalyst for the stock.

Anywhere Real Estate Soars on Acquisition Clearance

"anywhere real estate ticker is H O S. That was definitely a gainer in today's session. Uh, finishing the day with a gain of about 17 1.5%. Compass also higher. We'll bring that one up 9 and a half% to the upside. anywhere real estate shares climbing uh to their highest level intraday since 2022 after announcing that its acquisition by Compass uh cleared regulators. So again, that deal getting done."

The commentary highlights Anywhere Real Estate (HOS) as a notable gainer, boosted by its acquisition by Compass clearing regulators. The discussion implies that the acquisition clearance has acted as a strong catalyst, driving the stock to intraday highs.

AbbVie Loses Potential Acquisition Catalyst in Revolution Medicines Deal

"Let's go to Avy. Ay, >> let's go to Avy. We love Pharma M&A news, of course, though this one supposedly uh apparently may not be happening. So Ay shares, ticker ABBV. So those are down just 0.8% 810 of 1% after hours. So the latest news here is that apparently the company saying that it's not in talks to acquire cancer drug maker Revolution Medicines because earlier we did get a report from the Wall Street Journal saying that they could be in advanced talks uh to purchase Revolution. That would have been a deal worth $20 billion. And you know rallied right now. >> Exactly. Yeah. And so very interesting now that we're getting uh this response from AVY clarifying that they are not in talks at the moment. But yeah, the acquisition would have given him a foothold in the pancreatic cancer market that's expected to expand 10fold to more than $3 billion by 2035 accord according to Bloomberg Intelligence and Revolution has a drug uh that it is leading that sector."

The commentary highlights that AbbVie (ABBV) has clarified it is not in talks to acquire Revolution Medicines, defusing earlier acquisition rumors that had suggested a potential $20 billion deal. This lost opportunity removes a catalyst that could have provided AbbVie with a significant entry into an expanding pancreatic cancer market, which is expected to grow substantially by 2035.

Loheed Martin Impacted by Trump's Dividend and Buyback Warning

"So, Loheed Martin, this is ticker LMT. It's down about 2%. Trump coming out today saying he will not permit dividends or stock buybacks for defense companies until problems are rectified including pay production of equipment and plants. So back in December he had kind of signaled this desire to meet with defense contractor execs and tell them to spend more on weapons development and not stock buyback. So we're seeing some of that action come to light today and yeah the stock down about 2%. Actually 3% now. Ah, it's moved even more."

The transcript discusses how Trump's recent remark regarding prohibiting dividends and stock buybacks for defense companies is negatively impacting Loheed Martin (LMT), with the stock falling from around 2% to 3%. The comment hints at potential operational or management concerns, and the reaction is immediate as the stock adjusts to the news.

Valero Positioned to Benefit from Eased Venezuela Sanctions

"Well, we'll kick it off with oil refiners like Valero Energy jumping 5% after reports the US will ease sanctions on Venezuela, which will allow the company to sell oil indefinitely. And that is boosting the oil refiners because Venezuela is known for its heavy crude oil, which requires a specialized refinery units to remove the impurities and break it down into high value products like gasoline uh and diesel. And less than half of US refineries have a Coker according to Bloomberg Intelligence, which is the specialized unit you need uh to do that."

The commentary highlights Valero Energy's potential upside as easing Venezuela sanctions could allow the company to sell oil indefinitely. This advantage is underscored by Valero's specialized refining capability—processing heavy crude oil that few US refineries can handle—making it well positioned relative to peers.

Mobileye Expands Robotics Capabilities with Strategic Acquisition

"All right, let's talk about Mobile Eye. Mobileite, ticker is MBLY. Uh it's the only one in the green, up by almost 1%. So they're acquiring an Israeli startup called Menty Robotics and an all cash and stock deal valued at around $900 million. So the self-driving car system company is aiming to expand their robotics capabilities. I feel like almost everything now is either robotics or self-driving. So they're going to pay 612 million in cash and as many as 26 million class A shares. Um with a deal they join leading car makers in the US and China. So again we're going to have competition in this space and they're also investing in a human humanoid robot."

The speaker discusses Mobileye (MBLY), noting that it is the only company in the green among those mentioned. Mobileye is making a strategic acquisition of Menty Robotics, a deal valued at around $900 million, aimed at expanding its robotics capabilities amid growing competition in self-driving technologies.

MicroStrategy's Mixed Momentum Amid MSCI Decision

"One more. One more, One more. Let's get to Michael Saylor strategy at formally MicroStrategy. IBM's TR their shares have been up as much as 6%. The stock has actually slumped almost 6% in the past year. Yeah, six zero. The reason why the climb, well, you have MSCI MSCI, they decided for now to keep digital asset treasury companies in stock market indexes. So I say for now, because they didn't close the door they said they're going to do this broader consultation. So they may do a potential crackdown in the future."

The commentary on MicroStrategy (ticker MSTR) underscores a mixed performance where shares have risen by 6% recently despite a 6% decline over the past year. The discussion centers on MSCI's decision to continue including digital asset treasury companies in its indexes, while also hinting at a potential future crackdown, adding a layer of uncertainty for investors.

MicroStrategy Rally Amid Index Inclusion News

"This all has to do with the index inclusion fight. So, Micro Strategy, also known as Strategy, up 4.3% in the pre-market trade. MCI indexes has shelved for now a plan to eject cryptoheavy firms like strategy from its major indexes. Has decided to keep these digital asset treasury companies in its stock market indexes for now. But it has says that it had launched a broader consultation on how these non-operating companies should be treated which does signal that there could still be a potential crackdown coming. But we know the index inclusion has been really important for these cryptoheavy firms. So we're seeing Micro Strategy uh rally this morning maybe in relief that the exclusion is not coming anytime soon."

The commentary notes that MicroStrategy (ticker MSTR) is witnessing a pre-market rally, driven by the news that index providers have decided to maintain crypto-heavy firms in their indexes despite broader consultations on potential regulatory changes. The sentiment is that relief from immediate exclusion pressures is fueling the stock's upward move.

Uncertainty Clouds InPost Rally

"Let's go to the Netherlands. Next, the parcel locker operator in post dealing with the delivery of bad news. Shares down 6 and a half%. >> Yeah, yesterday we saw massive gains for that company um because it announced a big takeover proposal and Sky News then reported that the bidder was the private equity firm Advent International, which already owns about 6.5% of impost um but has been selling a lot of that stick in recent years. Um and this followed a period for Impost of being one of the most shorted stocks in Europe. But now today uh we are after this massive rally that we saw yesterday, we are seeing a big drop in the shares. And analysts are saying that this was triggered by profit taking after after the rally yesterday. And that profit taking might also be because it's still really unclear, really uncertain whether a takeover bid would actually materialize. And so investors are maybe not quite keen to stick around until they they figure that out. Um, but there'll be more to follow there and probably more announcements coming from Impost at some point later."

The discussion on InPost focuses on the volatility seen after a sharp rally driven by takeover news. With shares down 6.5% today and uncertainty surrounding the potential takeover bid, the commentary suggests short-term caution as profit taking sets in and clarity remains elusive.

Atlas Copco Positioned for Industrial Recovery

"Turning to Sweden next. The industrial company Atlas Copco gaining today. Why? >> Yeah. So Atlas Copco is a company that makes things like vacuum solutions and compressors. So on the face of it, that doesn't sound super interesting, but it is a major Swedish industrial company and if it is doing well, it tells us a lot about the recovery in the industrial sector and where momentum is actually kind of picking up. Um and so Atlas Copco was just upgraded at Bernstein with analysts saying that earnings had bottomed and that a rebound was on the way. Um and this is something that other analysts have flagged as well previously saying that orders will likely start kind of flowing through again because of manufacturing and construction activity starting to recover. Companies are once again starting to invest in equipment because there is now greater clarity on tariffs. There's more solid demand. um you know just yesterday we had chip makers moving higher because of an expected recovery in industrial end markets. So this is all really part of the same story of companies kind of growing more confident wanting to spend their money and sometimes part of that is that they do need a big industrial compressor and Atlas Copco will be there to provide that."

The commentary highlights Atlas Copco's positive outlook as evidenced by a recent upgrade at Bernstein. The speaker explains that the company is a bellwether for the industrial recovery, with improving earnings and renewed order flow driven by clearer tariffs and solid manufacturing demand.

Oil Price Impact on European Oil Stocks

"So, all eyes on oil prices. We're looking at that situation in Venezuela. How are we seeing the response in oil companies? >> Yeah. Well, it's it's a little bit weak. So BP, Shell, Total, NE, all of them were down this morning on this latest development. So Trump said that Venezuela would send 50 million barrels of oil to the US, which is worth about 2.8 billion. And that announcement sent oil prices falling. And of course, when oil prices are weak, shares in oil companies do tend to follow. Um, it's worth saying that the amount of oil that we're talking about here is fairly insignificant economically and it will not necessarily meaningfully change the supply in the market, but politically, of course, it is a big move and it has consequences even beyond Venezuela as well."

The speaker discusses how political maneuvers in Venezuela, including a 50 million barrel oil shipment announced by Trump, have led to weaker oil prices, impacting European oil stocks. Although the economic quantity is minor, the political implications are significant and could affect market sentiment in the short term.

Ventix Acquisition Talks Spark Volatile Trading Action

"Yeah, so the biggest one that I'm looking at right now and after hours is Ventix. This is ticker VTYX. So shares are up nearly 60% right now. There was a Wall Street Journal report that Eli Liy is in advance talks to acquire this biotech company for more than 1 billion which is nearly double or yeah nearly double um where it was valued as of Tuesday afternoon uh which is at about 550 million. So um shares were actually halted for for volatility right after we like closed the market but they're back up. Um, this is a company that specializes in developing medication for inflammatory diseases. So, things like Crohn's and rheumatoid arthritis and it had been a little bit of a like a rumored acquisition target in the space."

Ventix (VTYX) is experiencing significant after-hours volatility with shares up nearly 60% following a Wall Street Journal report that Eli Lilly is in advanced talks to acquire the biotech for over 1 billion, nearly doubling its previous valuation. The company, which specializes in treatments for inflammatory diseases, is a rumored acquisition target, adding further catalyst to its short-term trading action.

Equifax under regulatory pricing scrutiny

"I do not understand what the credit bureaus are doing with their pricing. They are inviting a lot of scrutiny that is only intensifying by the day."

Bill Py, the Federal Housing Finance Agency director, criticizes the credit bureaus' pricing strategy, suggesting that the increasing regulatory scrutiny could further pressure Equifax shares, which had already been falling. His comment implies potential negative impacts on the company's performance due to its pricing practices.

Lockheed Martin Benefiting from Major Pentagon Deal

"Loheed Martin, of course, we are seeing this stock in the green earlier up as much as about 5.3% now pairing a bit, but this after it struck a deal with the Pentagon to triple production of its Patriot air defense missile, which we know is deployed not only by the United States, but about 17 other countries. So, really critical here. This agreement is really clearing the way for negotiations over a 7-year contract to increase production of this. And this is really just a broader US push to ramp up weapons output. So you are seeing the street clearly liking this stock."

The insight focuses on Lockheed Martin (LMT) showing positive momentum after securing a Pentagon deal that triples production of its Patriot air defense missile. The deal not only supports near-term gains but also paves the way for a potential 7-year production contract, underscoring a long-term catalyst amid a broader defense industry push.

Sandisk Rally Driven by Underserved Memory Market

"Well, this stock has really rallied today, up as much as 25%. That's the biggest jump that we've seen in terms of a single day basis in nearly a year. This, of course, is commentary from Nvidia's Jensen Wong. He said that the memory storage chip market is quote unquote underserved. And that just sent that stock rallying. We're seeing shares up about 24% right now as we speak. The best performing stock in the S&P 500 simply off of what Jensen Wong has to say."

The speaker highlights Sandisk (SN) experiencing a significant rally, driven by comments from Nvidia's Jensen Wong regarding an underserved memory storage chip market. This company-specific insight points out the stock's impressive day-to-day performance, suggesting strong market momentum.

Tesla Losing Ground to BYD in Key International Markets

"Then they also outperformed Tesla in the UK market. That's the second largest market for plug-in cars. So we've heard this like Tesla already gave up that title of world's top seller to BYD. I spend a week in Paris ducking in tiny little electric useless cars. I hate them, and I could report I was in at least three BYDs. Yeah. And they're way more car than a Tesla. They're they're way more fancier. They're just you're inside."

The speaker contrasts Tesla's recent performance with BYD, noting that Tesla has lost its status as the world's top seller in key markets like the UK. The commentary, laced with personal observations and comparisons, argues that BYD's superior product appeal may challenge Tesla's dominance, hinting at potential short-term headwinds for Tesla.

Trade Call on OneStream: Buy Candidate Under Acquisition Talks

+0.08%current return

"this is financial software maker one stream taker OS. Um, their shares um they they've [clears throat] sunk 35% in the past year, but before the open, they're up as much as 28%. And sources saying buy from HG, it's in advanced talks to buy the company. The deal could be announced in the coming days, but it's a company has a market value of $4.5 billion. Um, its shareholders like KKR, they raised 563 million in an IPO back in 2024. Um, and then you have HG, they manage about 100 billion assets um for institutional private investors. So, we'll see if this happens."

The speaker provides an actionable trade call on OneStream (ticker OS), noting a significant intraday rebound after a steep decline over the past year. The commentary suggests that advanced acquisition talks with HG could serve as a near-term catalyst, positioning the stock for a potential upside if the deal materializes soon.

Nvidia's New AI Data Center Processor Signals Potential Upside

"All right, I want to start with Nvidia, ticker NVDA. Their shares have been up um nearly 1%. Big day at CES yesterday. Um CEO Jensen Wong he said the Reuben data center processor is in production. Uh demand is strong and he actually said it's five times better at running AI software than its predecessor. You know the Blackwell chips. Um he said that Rubenbased systems are going to be cheaper to run than Blackwell versions because they have smaller number of components too. But you have customers like Microsoft. They're going to be among the first to use this new hardware in the second half of the year. So that's a date he's starting to give out."

The speaker highlights Nvidia's announcement regarding its new Reuben data center processor, noting its improved AI performance and cost efficiencies compared to previous generations. The mention of strong demand and early adoption by key customers like Microsoft underscores potential near-to-medium-term upside as production ramps up later in the year.

Microchip's Strong Q3 Sales Forecast Drives Share Gains

"Taking a look at Microchip today as well. So, ticker MCHP, those shares soaring up more than 8% now. So, extending opening gains and that is because we did get a net sales forecast for them for the third quarter. That beat the average analyst estimate. The company is looking at $1.19 billion for the period versus the average estimate of $1.14 billion. They also said that bookings activity was very strong in December and Morgan Stanley analysts expecting the company's estimates to rise again in 2026 but probably less likely for 2027. Meanwhile, Caner upgrading the stock to overweight from neutral. So, a lot of uh good news to be had from Extra."

The insight highlights Microchip's robust performance as shares jump over 8% on a strong Q3 net sales forecast that exceeded analyst expectations. The focus is on the company's promising sales numbers for the third quarter and further potential upgrades, suggesting a positive near-term outlook.

Vistra's Strategic M&A Move to Bolster Power Assets

"Absolutely, Scarlet. Let's take a look at Vista. So, VST, and those shares are up nearly 4% today. So, they're making a play. It's M&A Tuesday, I guess, for this company. uh they're going to be paying $4 billion for 10 natural gas firepower plants in the US Northeast and Texas which were previously owned by Cogentric Energy. So this move essentially seen uh as a play by Vistra to accumulate power assets because they're going to try and meet the demand uh for power from data center buildouts. And so the acquisition of course gives them uh access to three major US grids uh in New England, Texas and a system that spans from New Jersey to Chicago. So this move is actually the latest of a series of acquisitions they've made over the past year. They paid $6.8 billion for a nuclear fleet in 2024 and $1.9 billion for seven gas plants in May. So this is the latest M&A move for them to meet that AI data center demand."

The commentary focuses on Vistra's recent acquisition of natural gas firepower plants for $4 billion, which is part of a broader M&A strategy to gather power assets to support growing data center power requirements. This acquisition follows other large deals, indicating a strategic pivot to meet AI-driven energy demands.

Nvidia's Progress on Reuben Data Center Processors

"All right, Paul, we're going to take a look at Nvidia today. Of course, the ticker NVDA, those shares are up 2%. And we did hear from CEO Jensen Wang at the CES trade show yesterday. He's saying that the company's highly anticipated Reuben data center processors. They're in production. They're on track for deployment. They're looking at sending them to customers in the second half of this year. So, digging more into this Reuben chip, right? Again, it's named after astronomer Vera Rubin. It is Nvidia's latest accelerator. Apparently, it's three and a half times better at training and five times better at running AI software than its predecessor, the famous Blackwell chips, of course. Um, and Nvidia, well, Jensen Wong also saying that the company has seen strong demand from customers in China for the H200 chip. Remember, that chip is currently under consideration by the Trump administration whether they're going to be able to sell it to China. Uh, so that's still pending, but uh, Jensen Wong saying that there's already demand lined up for that chip."

The segment highlights Nvidia's progress as CEO Jensen Wang confirms that the new Reuben data center processors are in production with deployment planned for the second half of the year. The chip shows significant performance improvements over its predecessor and there is notable demand for another chip, H200, despite pending regulatory review in China.

Semiconductor Recovery Boosted by Microchip Sales Outlook

"Got some traders watching Europe tech firms for non-micro gains. Yeah, so Microchip over in in the US has said that it expects higher sales than previously thought. Um, so that's taken by the market as a sign of recovery for industrial and automotive end markets. So this is a good day then for semiconductor companies in Europe that are exposed in particular to those end markets. And there's been a lot of weakness recently in those end markets and really a lot of uncertainty about when that would lift. Um so the fact that microchip has signaled a rebound there is really reassuring for Infinian and ST Micro especially given that those two actually had said previously that the quarter that ended in December would be below seasonal trend."

The segment discusses a positive shift in the semiconductor industry, citing Microchip's forecast for higher sales as an indicator of recovery in industrial and automotive sectors. This commentary suggests that the current rebound could help narrow the performance gap between traditional semiconductor names and those more exposed to the AI sector.

Ocado Gains on Positive Catalyst Watch

"Okado, meanwhile, delivering fresh gains. This is after the latest report by analysts JP Morgan. They were placed on a positive catalyst watch by JP Morgan. There was also a monthly report from an industry researcher that showed that Aardo was once again the UK's fastest growing grower in December. Um so there's kind of two positive things there for Ricardo. Um if we go back to the positive catalyst watch from JP Morgan, they said that there is now greater operational stability at the company after some recent setbacks. Of course we remember the biggest one was when Aardo Okardo's biggest customer Kroger announced it would close three automated warehouses that were operated by Aardo and that had sent the shares plunging and really hurt investor confidence in the company. But now there is a lot more clarity on that partnership with Kroger. There is also Cardo going to be pursuing more deals in more markets after ending some exclusivity agreements and JP Morgan analysts also said that the balance sheet looks much sturdier, much stronger."

Ocado appears to be benefiting from renewed investor confidence after being placed on a positive catalyst watch by JP Morgan. Improved operational stability, clarified partnerships with major clients like Kroger, and a stronger balance sheet are highlighted as key factors that could support future performance.

Next Retail's Strong Christmas Sales but Cautious Outlook

"next boosted its profit target for a fifth time this financial year and that was thanks to really strong sales over the Christmas period. So, the sales were super strong in international markets in particular. But even in the UK where expectations were a little bit more muted, uh growth was actually ahead of those estimates as well. Um but it's not because the Christmas spirit was strong that 2026 will necessarily be uh golden either. So next did warn that profit in sales would grow at a slower pace in the year ahead. Um it blamed rising unemployment and and slowing wage growth which means of course that there will be more constrained consumer spending, more uh more uh uncertainty, less money to to splurge on nice clothes and you know next is usually quite cautious with its guidance."

The commentary on Next highlights that while the retailer enjoyed robust Christmas sales both internationally and in the UK, management warned of a slower pace in profit growth over the coming year due to factors like rising unemployment and slowing wage growth. This nuanced view suggests optimism tempered by caution regarding future consumer spending.

Adidas Faces Double Downgrade as Casualization Trend Ends

"And finally in our last 30 seconds, don't correct me on the pronunciation, but Adidas is in the news as well. Yes. Uh sinking 6% in Germany. A double downgrade from Bank of America. They are now calling the 20-year casualization trend largely complete."

Adidas is facing headwinds as its stock sinks 6% in Germany following a double downgrade by Bank of America. The downgrade commentary suggests that the long-standing casualization trend, which has buoyed the brand for 20 years, is now coming to an end, putting pressure on future performance.

Novo Nordisk's Weight Loss Pill Launch Positions it as Market Contender

"Nova Nordisk is in the news as well, of course, because the WGOI pill is in the US market now. Nova Nordisk really making some headlines in the European session. The best performing stock in the Euro stock 600. Their ADRs are higher by just shy of 4%. The weight loss pill launches in the US just 2 weeks after it received US regulatory approval for the drug. It will be broadly available through 70,000ies across the US. The investor focus will be on the volume benefit as it tries to compete with Eli Liy for market share in the space and most importantly on the margins."

Novo Nordisk is highlighted as a strong performer in Europe, buoyed by its recent US launch of a weight loss pill following regulatory approval. The near-term launch, occurring just 2 weeks post-approval, positions the company to capture volume benefits and market share against competitors, with margins remaining a key focus.

Microchip Raises Guidance Amid Early Recovery in Analog Chip Sector

"There's a stock called Microchip. This isn't just the microchip sector in particular that you're looking at. I had to double double second guess that myself. Microchip. Um it's in the news because the analog chip maker had lifted its sales forecast and essentially points to an early recovery in the analog chip sector. It counts Texas Instruments as one of its main competitors. We're actually seeing the likes of many of these analog chip makers rally off the back of this positive forecast from Microchip. Now, the analog chip sector has been experiencing a cyclical slump due to an inventory glut and weakening demand, especially from the auto space, but the CEO said that activity booking was very strong in the December quarter, and they raised their guidance off the back of that."

Microchip is noted for raising its sales forecast, signaling an early recovery in the analog chip sector despite previous cyclical challenges. The improved guidance, contrasted with competitors like Texas Instruments, indicates a strengthening demand and better-than-expected activity in the December quarter.

AVA Surges 30% on Nvidia Autonomous Driving Tech Partnership

"Now this is a a liar company, a sensor technology essentially. It is surging in pre-market. That's what you need to know. Up over 30%, Nathan, after Nvidia chose its laserbased technology to power its autonomous driving platform. It comes alongside a a string of of new launches from Nvidia at the CES trade show in Las Vegas. One of those was a new vehicle platform called Alpameo, which allows autonomous cars to reason in the real world, essentially think their way out of unexpected situations. So Nvidia is aiming to extend their reach of its technology and it's including uh reaching out into uh autonomous driving platforms with this new agreement with the AVA LAR company."

The segment notes that AVA, a sensor technology company, is surging over 30% in pre-market trading following Nvidia's decision to incorporate its laser-based technology for autonomous driving. The announcement, made in the context of Nvidia's CES launches, positions AVA as a noteworthy player in the evolving autonomous driving market.

Vistra Deepens AI Bet with $4 Billion Gas Fleet Acquisition

"Vistra is uh higher by nearly 5% in pre-market trade. It's the largest competitive power generator in the US and they have agreed to buy a gas power fleet for $4 billion as it deepens its bet on this energy race around AI. The deal includes 10 power plants and these gas powered power plants are seen as ideal sources for that aroundthe-clock data center demand uh that this AI race will need. So Vistra jumping off of this news higher by 4.7%."

The commentary highlights Vistra's strategic move to acquire a gas power fleet for $4 billion, positioning itself to meet growing AI-driven data center demand. The news catalyzed a roughly 5% pre-market rise, reinforcing the company's competitive strength in the US power sector.

Adidas Faces Diminishing Growth Prospects Amid Double Downgrade

"Adidas was double downgraded by Bank of America. The analysts have said that they expect lower growth for the company going forward. Also said that investor interest in that sector was really starting to wane. Um in some what some said was is quite harsh. They said that the company's brand upcycle was old news. Um, so that maybe seems to indicate that the company might not be able to kind of always ride the wave of consumer enthusiasm for uh its retro sneakers, which was really what has been driving the growth over the last couple of years. Um, and this comes just a few weeks after Nike, which is obviously the most direct competitor, uh, warned that sales would also take a hit for them with a weakness in China in particular. So, it seems that across the board for those spots where stocks, there's maybe a lack of catalyst going forward and some weakness that we need to take into account."

Chloe Malay outlines that Adidas was double downgraded by Bank of America, with analysts expecting lower growth due to an outdated brand upcycle and waning investor interest. She emphasizes that issues in competitive markets, such as the recent warning from Nike regarding China, further highlight a potential lack of catalysts for Adidas in the near term.

Estee Lauder: Double Upgrade Sparks Turnaround Play

"Yes. But where we were seeing a double upgrade, that was with Estee Lauder. We did see shares higher, and this is a company that's been battered. If you look at the past few years from this stock in particular, we did see shares of the company up about 40% to end 2025. But if you look at some of the years prior to that, we were seeing some pretty substantial declines. But the reason that we are getting a double upgrade over here from Raymond James are saying that uh they essentially think that fiscal 2025 marked the earnings trough for this company and they said that the turnaround story now shifts to quote unquote execution. So we'll have to wait and see whether or not this is actually the case, but they did raise the price target making it a Wall Street high. I just want to point out and I'm just going back to I don't know if this was the all-time high. It is down 71% from January 4th of 2022."

Raymond James has issued a double upgrade on Estee Lauder, suggesting that fiscal 2025 marks the earnings trough for the company. The commentary highlights the stock's past volatility, noting a 40% rise leading to end-2025 against previous substantial declines, and points out that a raised price target combined with minimal sell recommendations could signal a potential turnaround.

Qualcomm's New AI-Enabled X2 Plus Processor

"Qualcomm is extending its push into the market for processors that are the heart of personal computers with its new X2 Plus processor. So it has two versions, one, one with a 10 computer core and one with six. This apparently includes powerful neural processing units that will make these computers work faster and go longer periods without needing a source of power. Pretty incredible. And we can expect to see a lot of announcements like this at the CES conference this week. It's going to be basically like a chess puffing conference for the tech company. So, expect those shares to keep moving."

Tim Stanbec highlights Qualcomm's launch of its new X2 Plus processor, which comes in dual configurations and features advanced neural processing units. The innovation is seen as a strong signal for near-term announcements at CES, suggesting positive momentum for the stock.

Goldman Buy Rating on Coinbase

-1.87%current return

"over at Goldman, one of the companies that is fairing well today is Coinbase. It got a buy rating there. I'm looking at shares up about 9% right now. Analysts there see growth potential from new products like tokenization and prediction markets as well. They also highlight the fact that their subscription service offerings have risen from 5% to 40% of their revenue over the past 5 years. So that could bode well for shares. Um they also say that the company deser deserves a higher multiple given the revenue that they've gotten and also recent underperformance makes it a good entry point. And then on the flip side of that actually it Toro got downgraded to neutral there. They said that margins are lagging peers due to a more competitive backdrop."

Goldman analysts are recommending a buy on Coinbase, citing significant revenue growth through increased subscription services and new product initiatives like tokenization and prediction markets. Despite some margin concerns relative to peers, the overall entry point is seen as attractive given recent underperformance.

Caution for Domestic Shell Producers as Demand Shifts Impact Diamondback Energy

"Diamondback energy uh ticker fang down 3.5% on the day today. As I mentioned, we did see a rotation out of some energy stocks, especially US focused shell oil producers. If more oil companies come online, we could see greater supply and lower prices, which wouldn't be good for these domestic shell producers. Some of them are already slowing down growth due to concern for a global gut developing."

The commentary highlights that Diamondback Energy (ticker FANG) is experiencing a decline as domestic shell oil producers face the risk of oversupply and lower prices, driven by more oil companies coming online. This negative catalyst suggests potential headwinds in the near term.

Estee Lauder Receives Strong Buy Upgrade with $130 Price Target

+5.35%current return

"Yes. Some more upgrade downgrade action. We're looking at Estee Lauder. That's ticker E. We're seeing shares higher right now. Up as much as 3.8% earlier, but pairing right now about up about 7/10en of a percent. This is after Raymond James hopped in raising their recommendation on the beauty company to a strong buy from market perform. But not only that, they also added Estee Lauder to uh the firm's analyst current favorites list. uh their price target is $130 which is the highest of all analysts uh that are tracked by Bloomberg on the street. So they're essentially talking about the fact that they think that fiscal 2025 marks the earnings trough and this turnaround story now shifts to quote unquote execution."

Raymond James upgraded Estee Lauder (E) to a strong buy with a price target of 130 and identified fiscal 2025 as the earnings trough. This signals a turnaround story focused on execution, making the stock an attractive long-term trade based on current momentum and analyst conviction.

Chevron Positioned to Benefit from Venezuelan Rebuild

"So I want to start with Chevron. Their shares have been up as much as 10%. It's the only American oil major currently operating Venezuela that was under a special U.S. permission. So it's really best positioned to immediately benefit from greater U.S. access. They produce about 20% of the country's oil under a sanctions waiver. They ship to the crude to U.S. refineries."

The speaker highlights Chevron as uniquely positioned among U.S. oil majors to benefit from the upcoming spending to rebuild Venezuela's energy infrastructure, given its special sanction waiver and significant operational presence in the country.

Chevron Positioned to Benefit from Venezuelan Rebuild

"I want to start with Chevron. Their shares have been up as much as 10%. Um, it's the only American oil major currently operating in Venezuela that was under a special US permission. So, it's really best positioned to to immediately benefit from greater US access. They produce about 20% of the country's oil under a sanctions waiver. They ship to the crude to US refineries."

The speaker highlights Chevron's unique position in Venezuela, emphasizing its ability to benefit immediately from US efforts to rebuild Venezuelan energy infrastructure due to a special US permission. The company produces 20% of Venezuela's oil under a sanctions waiver and is thus positioned for near-term upside.

Goldman Sachs Upgrades Coinbase to Buy

-96.49%final return

"Coinbase, let's take a look at Coinbase that is doing really well today. So ticker COI and those shares are up more than 7%. It's set for the biggest gain since October and it's all about the Goldman Sachs upgrade. So Goldman Sachs upgraded the stock to buy from neutral previously and the price target now at $33. So that's about a 20% upside from current levels. Gold analysts saying that Coinbase's rapidly growing subscription and services offerings have risen from less than 5% to 40% revenue over the past 5 years. And so they're thinking now that it does deserve a higher PE and that's why they're upgrading that stock."

Goldman Sachs has upgraded Coinbase from neutral to buy, citing its rapidly growing subscription and service revenues which have increased significantly over the past five years. The upgrade comes with a price target of 33, suggesting about a 20% upside from current levels, making this an actionable trade call for investors.

QXO Gains Backed by $1B Financing

"This is a bit of a niche one. So QXO is a buildings products distribution company. Essentially it's a publicly traded private equity style rollup in the buildings products industry. Now sources have told Bloomberg that an investor group led by Apollo Global Management has agreed to invest more than $1 billion and we're seeing shares of QXO up 8.3%. Obviously, this backing, this more financing would give the company more ammunition to pursue its expansions and further acquisitions."

The commentary highlights QXO as a niche buildings products distribution company that, following a significant $1 billion investment led by Apollo Global Management, is seeing its shares rise by 8.3%. The financing is interpreted as a catalyst providing the company with resources to expand and execute further acquisitions.

Rheinmetall rallies amid Venezuela-driven defense optimism

"Well, all of them really are in the green this morning. So, we're seeing Ryan Metal in particular up quite strongly, but names like Hansel uh also in Germany and then Leonardo in Italy, Saab in Sweden. All of them are are moving higher this morning. And that's of course on the back of this situation in Venezuela. We've got heightened geopolitical tensions that tend to kind of push investors towards those defense stocks. And given how much uncertainty there is around this particular situation with questions about what's coming next and what it really means for US foreign policy going forward as well, it's really not surprising to see those really significant uh moves across that defense sector. We're talking about a move of as much as 7% for Ryan Mattel this morning."

The commentary highlights a strong rally in European defense stocks, with a particular focus on Rheinmetall, which reportedly surged by as much as 7% this morning. The rise is attributed to heightened geopolitical tensions stemming from the situation in Venezuela and uncertainties around US foreign policy, suggesting increased defense spending and strategic shifts in Europe.

ASML Positioned for AI-Driven Memory Chip Demand

"Yeah, absolutely. And that's good news for ASML, which rose that morning quite strongly as well um to actually to a record. And that's because of a a couple of things. But first, we had an upgrade from Bernstein analysts um saying that ASML will benefit a lot from a memory chip demand, which is of course driven by AI. Um but ASML is also riding the wave of quite a lot of enthusiasm in general for tech and AI stocks this morning. Um there's still concerns about the AI bubble, but uh investors are still continuing to put money into that AI theme that we saw uh TSMC shares in particular, for example, rallying massively after Goldman Sachs lifted the price target by 35% for that company, saying that AI will be a really a multi-year growth engine for for TSMC. and ASML is a big supplier to that company."

The speaker highlights that ASML is benefiting from an upgrade by Bernstein analysts, with expectations of strong performance driven by memory chip demand and the broader AI theme. Despite some concerns around an AI bubble, the overall sentiment is bullish as ASML is seen as a key supplier in the tech ecosystem, reinforcing its near-term positive outlook.

Negative Outlook on Tesla Amid EV Rivalry

"Yeah, I mean let's might as well skip to it. That's another uh peer that we're looking at. We see shares of Tesla that ended lower by about 2.6%. This is actually its seventh straight day of losses as we look at that continued streak. Uh, but we did see shares of Tesla that were up about 11% on the day. But we do know that Tesla has essentially given up its title as the world's top seller of EV cars to China's BYD. We were talking about this a bit earlier. Maybe people may not be as familiar with the car BYD in the US, but it's certainly very popular."

The speaker highlights Tesla's recent underperformance, noting a 2.6% drop and a seventh consecutive day of losses even though there was an intraday recovery. There is a strong sentiment that Tesla has lost its status as the top EV seller to BYD, casting doubt on its current strategy as it shifts focus toward autonomous vehicles and AI ambitions.

Wayfair's Stellar Performance Highlighted Amid Tariff Relief

"I'm looking at RH as well as Wayfair. We're seeing shares of both companies charging higher. But, uh we do know that RH really did have a tough year. If you look just last year, it lost more than half of its value. So just to put that into context in terms of the move that we are seeing today. But Wayfair did have a pretty stellar year for 25 to say the least% to the 127% to the upside."

The speaker contrasts the performance of two furniture companies, noting that while RH suffered major losses last year, Wayfair delivered an impressive performance with gains reportedly ranging from 25% to as high as 127% upside over the past year. Tariff delays appear to have positively influenced share movements.

Tesla Loses Top Seller Status Amid Rising Competition

"Well, speaking of stock that is struggling today, uh Tesla is moving to the downside by about 2%. What's going on with Tesla? >> Yeah, Tesla, we're seeing shares sliding. Uh this is after just an 11% gain that we saw uh year to date for 2025, but we did see that Tesla's essentially giving up its title as the world's top seller of EVs to a Chinese competitor, BYD. I mean, it may not be as popular in the United States, but super super popular in uh China."

The discussion casts a negative light on Tesla as its shares decline by 2% after an earlier year-to-date gain. The speaker points out that Tesla is losing its top EV seller status to BYD, highlighting growing competitive pressure, particularly in China, which undermines its domestic prominence.

Under Armour Trading Opportunity Amid Rebound

"Uh looking at Under Armour. We saw shares that climbed as much as 10% today. This is the most in nearly seven months, but I mean this is also a stock that's been quite battered. Lost 40% of its value last year. Uh we did see what four back-to-back years of declines for this company, but today we're seeing it in the green. And this is because UBS analysts said that they see improving EPS and sales growth boosting the stock's valuation. So it seems as though some traders out in the market are taking this and clearly buying in on it."

The speaker highlights Under Armour's significant intraday rebound with a 10% climb, noting its troubled past with a 40% decline last year and four consecutive years of losses. UBS analysts are credited with the optimism, citing improving EPS and sales growth. This creates a contrast between its past performance and its current positive momentum.

RH shares break technical resistance amid tariff delay

"Yeah, I mean NEO has definitely been one of those shares that's been hugely volatile all year. We were talking about RH used to be Restoration Hardware I guess with uh Natalia earlier and that's been a mover because of Donald Trump. Actually it's been a mover because of Donald Trump and RH shares are up by almost double digits. It's really gaining after a tariff delay. Shares are trading above a 200 DMA for the first time since March DMA as in moving day average. And if you look at all the technical analysis, the Fibonacci in January high to March low, it's around $22. But RH I was trying to Google it because I've been to an RH rooftop in um Chelsea. They have a nice restaurant and I was looking whether they're connected and I think they are, but it's interesting to see um furniture retailers really um doing well, but they really have to also diversify their sourcing ahead of the tariffs. um this year and next in 2027."

The speaker provides detailed commentary on RH (Restoration Hardware) shares highlighting a technical breakout above the 200 DMA and a key Fibonacci support level at $22 after a tariff delay. The discussion underscores both the strong price action and potential sourcing risks for the furniture retailer.

Tariff Delay Benefits for Furniture Retailers

"President Trump delayed the tariff increases on upholstered furniture, kitchen cabinets, and vanities. The higher tariffs, they were supposed to take effect yesterday, but now set to take effect January 1st of 2027. Remember also with tariffs, we're still waiting for some word from the Supreme Court on tariffs overall and those companies that have already paid them could be due for a refund."

The delayed tariff increases, now postponed until January 1st, 2027, should ease near-term cost pressures for furniture companies such as Restoration Hardware, potentially benefiting their margins.

Concerns over Tesla's European Delivery Performance

"in the pre-market, Tesla is uh, higher in the pre-market and as it is always, one of the most actively traded higher this morning only because it's taken such a beating over the past week or so. Uh, they finished off a pretty dismal year in Europe. Steep declines in several of the region's major markets for new car sales. Uh, the company registered only 1,942 cars last month in France. Uh that's down 66% from a year earlier. Sales plunged 71% in Sweden at 44% in Spain. Uh deliveries dropping in all three countries for the full year. Now analysts are expecting Tesla to report later today that it's global vehicle deliveries fell around 11% in the fourth quarter."

Tesla's European delivery performance has been dismal with steep declines in key markets, raising concerns ahead of its expected global delivery report later today.

Tesla Q4 Delivery Outlook and European Demand Concerns

"Now, analysts are expecting Tesla to report later today that its global vehicle deliveries fell around 11% in the fourth quarter. That's actually worse than the composite from Bloomberg analysts. Tesla took the unusual step earlier this week of publishing that analysts estimate that was pessimistic again calling for a 15% drop. Demand for Tesla slumping across most of Europe throughout last year, in part because of the blowback over the CEO, Elon Musk, and, you know, the things that he had to say about Europe and supporting some right wing politicians there in countries including in Germany and the U.K."

Tesla is expected to report a significant decline in Q4 deliveries with an anticipated 11% decrease, which underperforms Bloomberg's expectations. The commentary highlights deteriorating European demand and concerns over the negative political fallout from CEO Elon Musk's remarks, adding uncertainty to the near-term outlook.

British American Tobacco Faces Earnings Headwinds from ITC Tax Hike

"Let's turn to British American Tobacco next. Shares are in the red there. What's driving that? >> Uh well, BAT is taking a hit because of its stake in ITC, which is the largest maker of cigarettes in India. And that company is taking a big hit because of a new excise duty to try and limit the smoking rate in India. We've got 250 million people smoking in India. That's the second highest population globally. For ITC it's not too exciting because we're talking about a tax hike of over 30% if we include other charges on cigarettes. This new tax, given that ITC gets over 40% of its revenue from cigarettes, could mean a big hit on volumes and earnings, triggering a 15% cut in earnings per share estimates for 2027 and 2028. It's a significant vulnerability for BAT, which holds about a 23% stake in ITC."

British American Tobacco is under pressure as its stake in ITC is adversely affected by a new excise duty on cigarettes in India. The significant tax hike—over 30%—is expected to reduce ITC's volumes and earnings, leading to a 15% cut in EPS estimates for 2027 and 2028, thereby negatively impacting BAT's outlook.

Orsted Rises amid Legal Challenge Against Wind Farm Suspension

"Let's turn to Orstead next, filing a legal complaint against US President Donald Trump's wind farm suspension. >> Yeah, um there was uh it's up this morningstead on the back of that and perhaps indicating that investors are happy that is kind of pushing back of against the Trump administration. Um the company said that the decision to suspend the lease of a wind project that was very close to being completed uh violates applicable law. Um and so all is calling for the suspension to be lifted uh until there's a final verdict from the court. The project which is called revolution wind has been targeted a couple of times by the Trump administration recently. Over the summer we had a stop work order. And then a judge ruled that construction could actually resume. Now that there's this lease suspension, it's kind of another setback, but there are some gains today on the fact that it's pushing back against those decisions."

Orsted is facing regulatory and legal challenges after suspending a wind project lease amid actions by the Trump administration. The company's stance that the suspension violates applicable law appears to have reassured investors, as evidenced by a modest share gain this morning.

British American Tobacco exposed to regulatory tax hikes

"Okay. And we're looking to at British American Tobacco this morning. Could a new excise duty on cigarettes affect their fortunes this year? Yeah, VAT has taken quite a bit of a hit this morning because of its stake in ITC which is itself taking a big hit. So ITC is India's largest maker of cigarettes and the shares plunged quite, quite impressively, quite massively after the government decided to impose a new duty on cigarettes. Um and that new duty would result in a tax hike of over 30% and the reason why the market reaction was so harsh is because that tax burden is much higher than anticipated and ITC is very vulnerable to it. It gets over 40% of its revenue from cigarettes. So this new tax would mean a really big hit on volumes, big hit on earnings of course um and it could lead to a hike in prices of at least 15% uh to kind of pass on that impact to consumers. And because BAT is ITC's largest shareholder, we've got a stake of about 23% um it means that BAT is quite exposed to the fortunes of ITC and we're seeing that reflected in in some weakness in those shares this morning."

The analysis points out that British American Tobacco is feeling the impact of a new excise duty on cigarettes, which has severely affected ITC, its major investment. The tax hike of over 30% is expected to pressure cigarette volumes and earnings, thereby negatively impacting BAT due to its sizeable stake in ITC.

Vestas sees improved wind turbine order momentum

"Yeah, absolutely. It seems that the prospects for that wind industry are improving and Vestas will be a big part of that. So, um JP Morgan analysts have said that the company had probably a lot more orders for wind turbines than expected in the fourth quarter. Um so that includes both onshore and offshore projects. It also includes a variety of markets and it would make it the second consecutive quarter of demand coming in above expectations for Vestas. So it seems that there is good momentum going there. Um and it's definitely good news for an industry that's had a really really tough year."

The commentary highlights improved fundamentals for Vestas, citing JP Morgan's observation of unexpectedly high wind turbine orders in Q4 across various markets, suggesting strong momentum in the wind energy sector.

Mixed Signals in Nike's Performance

"We have to talk about Nike. Shares are up by more than 4%. That's after its CEO, Elliot Hill, reportedly bought $1 million worth of shares. And of course, this comes after Nike shares rallied last week after Apple CEO Tim Cook bought shares and he doubled his stake which is also signaling confidence in Hill strategy. But insiders buying, we like to see that, Nike is on track for its fourth year of decline. Oh, it's its fourth year of declines and the stock is now down some 65% off its all-time highs in 2021."

The commentary on Nike underscores a mixed outlook: while insider buying, including significant moves by CEO Elliot Hill and board member Tim Cook, signals confidence, the company's fourth consecutive year of decline and a 65% drop from its all-time highs introduce substantial concerns for long‐term performance.

Broadening AI Rally and Bull Market Outlook

"Talk to us about the broader market because we are pausing in our Santa rally, but we still have a couple of days. We could make it up. We still have a couple of or maybe a couple Yes, couple of days until I think two days after January and it's looking good because the S&P is up 17% this year. We're entering our fourth year of the bull market. And I think if there's a thing to note this year, it's that the AI rally has broadened. Remember in the past years it's just Nvidia, Nvidia, Nvidia. Nvidia is now just the 71st ranking in the S&P 500. The very first are data companies that really benefit from this whole AI rally. I mean, they're companies not a lot of people have heard of. SanDisk, it's up 600%. Western Digital. We used to use SanDisk all the time back in the day."

The broader market remains bullish with the S&P up 17% and a prolonged bull market, while the AI rally is diversifying beyond traditional names like Nvidia to include lesser-known data companies.

Corep Therapeutics Slumps After Drug Rejection

"You're also looking at some biotechs and and one ticker co. It's not Cortiseps like The Last of Us, but it's what? >> Corep. So, Corsip therapeutics stock is down by almost 50%. That's after regulators rejected the company's drug to treat a form of high blood pressure. So we know that with biotech companies whenever there's a treatment and there's a rejection the stock really plunges. So this is the lowest since at least 2024. I was bracing myself for something more drastic but at least when I go to since s functional bloomberg terminal is just till 2024. So it's the drug that aims to treat patients with hypertension and too much of those hor too much of those hormone cortisol. So the stock is now down."

Corsip Therapeutics is facing a steep decline, down nearly 50% following regulatory rejection of its hypertension drug, highlighting significant near-term risks in the biotech sector.

Nike Turnaround Signal from CEO Buying

"Nike for one, ticker is NIK. >> [music] >> Nike stock is up by around four and a half percent and that's after it CEO Elliot Hill reportedly bought a purchase of around $1 million worth of shares. And we know that just last week stocks rallied because Apple Cook CE Apple Apple CEO Tim Cook also bought $3 million worth of shares. This move really doubled his personal stake and signaled confidence in a turnaround strategy laid by Hill. And Nike has just been struggling throughout the year, but maybe this could be the turnaround for them. But they've seen weaker quarterly margins, luggage sales in China, and even for Converse."

Nike appears to be at a potential turnaround point as CEO Elliot Hill's purchase signals confidence despite the stock struggling year-to-date and facing margin pressures.

Memory Chip Industry Outperforms amid Sector Rotation

"Now, if everybody this morning goes to their Bloomberg terminal and type MRR, I think that stands for member rank returns. going to go to year to date. You look at the S&P 500 index, the best performers since the start of the year. Number one, SanDisk uh up 567%. Western Digital up 291%. And then you have Micron Technology, Seagate Technology. Anyway, you you get the picture. All four of these stocks, John, have to do with data storage and the memory chip industry. So if you maybe could look go all the way back to January this year and decide where to put your money, it wasn't in the MAG7s. It was actually in the memory chip industry. SanDisk, Western Digital, Micron, uh the big memory chip maker, and its competitor Seagate. All the best performing stocks in the S&P 500 for 2025. If you do look at the bottom though, there are some retailers down there, which I think is just showing you that there were some companies that did struggle with tariffs."

The speaker outlines that the memory chip sector, represented by companies such as SanDisk, Western Digital, Micron Technology, and Seagate Technology, has been the standout performer in the S&P 500 year to date, especially looking ahead to 2025. This sector outpaced traditional MAG7 stocks, contrasting with struggling retail companies impacted by tariffs, suggesting a strong sector rotation towards data storage.

Nike CEO Share Buys Signal Turnaround Confidence

"Nike making headlines this morning. The shares are up just over 2%, up 2.2%. This comes after their relatively new CEO, Elliot Hill, reported a purchase of about $1 million worth of shares. That transaction occurred on Monday. Now, 1 million doesn't sound like a lot, but it does come a week after Apple's Tim Cook doubled his personal holdings of Nike shares, adding $3 million worth to his personal stake buying Nike shares. Why? I don't know. Yes, he is signaling more confidence in the new CEO's turnaround strategy for Nike. Perhaps the new CEO, Elliot Hill, has been in the seat since October 2024 and trying to convince investors of his turnaround strategy. Now, Nike shares are still in the red for the year, down around 19%, but there's been a lot of retailers who have been struggling."

The commentary details recent share purchases by Nike's new CEO, Elliot Hill, and highlights a similar action by Apple's Tim Cook, suggesting growing confidence in Nike's turnaround strategy despite a 19% YTD decline. The narrative implies that these insider moves may serve as a positive signal for investors betting on a recovery.

Vanda Pharmaceuticals FDA Approval Sparks Pre-Market Jump

"Vanda Pharmaceuticals is jumping in pre-market up 22%. Because it's gotten FDA approval for its drug in the prevention of motion induced sickness. It's actually the first drug to be approved for this sickness in over 40 years. So, there's going to be a new drug on the market in the coming months that perhaps can help you with sickness out at sea, maybe sickness in the car when you're driving to grandma's for New Year's Day as well. But um it essentially works by blocking a brain receptor that's linked to nausea and vomiting."

The speaker highlights that Vanda Pharmaceuticals is experiencing a 22% pre-market jump due to FDA approval for its novel drug aimed at preventing motion-induced sickness. This event marks the first such approval in over four decades, indicating a potentially significant market catalyst as the new drug is expected to launch in the coming months.

OceanFirst Financial Shares Decline Post-Acquisition

"I'm looking at shares of Ocean Ocean First Financial Corp. That's ticker OCFC. We're seeing shares that ended lower by more than 6%. This is after the company agreed to buy Flushing Financial. So, this is a bank uh that delivers commercial and residential financing services. It's about $1 billion in market cap. So, not a massive company that we're talking about."

OceanFirst Financial (OCFC) saw its shares drop over 6% following its acquisition of Flushing Financial, indicating market concerns. Despite the acquisition move aimed at expanding its financing services, the bank's relatively modest $1 billion market cap may limit its impact, reflecting a cautious investor sentiment.

Ultragenyx Rebounds After Volatile Session

"Yeah, here's one that is trading a little bit like a meme stock as they often do in the sector. This is ultragenics pharmaceutical that is ticker rare. share sore today looks like 15% here. That is the biggest move since January of 2020. Uh Jeffrey's analysts say the stock could rebound in 2026. So what happened here was it actually plunged more than 40% yesterday and this is a somewhat of a recovery here. Uh Jeffrey's also giving it a little bit of a boost with its positive outlook. Analysts highlight that the company is maintaining 2027 profitability guidance and will provide guidance on exposure reductions in early 2026. These stocks often see really big swings in either direction here to the upside today."

Ultragenyx, trading under ticker RARE, experienced a 15% surge after a sharp 40% plunge the previous day. Analysts are optimistic about a rebound in 2026, supported by maintained profitability guidance and upcoming exposure reduction plans, though the stock remains volatile like many meme stocks in the biotech sector.

Meta Platform Acquires AI Agent

"The latest deal is Meta Platform set to buy an AI agent with Chinese roots. The company is called Manis. It is based in Singapore. Shares of Meta are up about 1.1% here into the close. This is part of its effort to build a business around its massive investment in AI. You guys remember back in November they announced $600 billion worth of investment in AI infrastructure. The deal values Manis at north of $2 billion according to sources. Uh it also marks a very rare US acquisition of an Asian technology company. Actually back in May, the venture capital firm Benchmark was criticized by lawmakers and other VCs for backing an AI company with ties to China. Apparently in this situation though, Manis' existing investors have been bought out by ATA's takeover and the company said that there will be no continuing Chinese ownership interests here."

Meta is embarking on an acquisition by buying Singapore-based AI agent Manis, valued over $2 billion, as part of its broader strategy to build an AI business. The deal is notable as a rare US acquisition of an Asian tech firm, reinforcing Meta's aggressive investment in AI infrastructure.

Ultragenyx Pharmaceutical Eyes Rebound Amid Catalyst

"Yes, another one. Uh we're seeing sharers of Ultragenics Pharmaceutical. This is ticker rare. Uh jumping for doubledigit uh returns right now on the day. We're seeing this as the best uh performance we've seen from the stock since August of 2024. This is a rebound after the stock hit a record low just yesterday on a study failure. We're seeing Jeff analyst saying that the stock could continue to rebound in 2026 ahead of late stage data update that is expected. So we do look at shares of the stock though down about 47% so far this year. So a brutal year. We'll have to see if it can actually eke out a turnaround. >> Yeah, nearly 10% of the float is short too. So, there's some negative sentiment uh out there."

The discussion on Ultragenyx Pharmaceutical points to a significant rebound rally following a record low due to a study failure, with analyst Jeff forecasting further recovery ahead of a late stage data update in 2026. Despite the impressive intraday performance, the stock's brutal year-to-date decline and high short interest inject uncertainty about its turnaround.

Molina Healthcare Positioned for Cyclical Upside

"Yes, looking at shares of Molina Healthcare. This has been a stock that's been hanging as the best performing stock in the S&P 500. I mean, I guess it's also important to point out that it's low trading activity right now, but we've been keeping our eyes on this name nonetheless. Uh, ticker Mo, we're seeing shares up as much as 4.8%. Now, it's up about 3.3%. But this is after Michael Bur, who people still maintain their eyes on. Uh, he made a Substack post that essentially was highlighting the company's record of strong expense ratios and underwriting results. Also praising the company's acquisition strategy. So this is just interesting as Michael Bur is essentially saying that this company is best positioned to emerge stronger as a cycle turns in relation to its competitors here at Carol and still somebody that everybody reads and takes very very seriously as as they should."

The commentary highlights Molina Healthcare's strong performance and solid fundamentals, including low expense ratios and effective acquisition strategy, as noted by Michael Bur. The stock is considered well positioned to benefit from an upcoming cycle turnaround.

OceanFirst Faces M&A-Driven Sell-Off

"No, yeah, this is one that I had to look into as well. A small company about one, uh, $1 million in market cap. It's a bank. As you mentioned, it's based in Tom's River, New Jersey. But the reason we're talking about this stock today, OCFC is the ticker there, is because it is one of the stocks that is down in the market today. Pairing has declined substantially, but earlier down as much as 11%. So a double digit dropper seeing there the worst day in more than two years for the stock. This is after it agreed to buy Flushing Financial. This is an all stock deal that includes an investment agreement with PE firm Warberg PINS. And, uh, this will be represented on the company's board."

OceanFirst Bank (OCFC), a very small bank with about $1 million market cap, is experiencing a steep decline—down as much as 11% and marking its worst day in over two years—amid M&A activity including an all-stock deal to acquire Flushing Financial.

Ultragenyx Pharmaceutical Rebound Potential

"Yes, this is ticker rare R A R E. We're seeing shares up about 13% right now. This is a company on the smaller side, about $96 million in market cap, but we are seeing shares up for double-digit gains. This is the biggest jump we've seen since August of 2024 for the stock. This is a rebound after, yes, or back in Monday. Yesterday we saw that shares hit a record low on a study failure. Jeffrey's analysts are talking about the fact that the stock could rebound into next year ahead of a late stage data update. So, we'll keep our eyes all over this biotech company, but not doing too hot this year either. Shares are down about 47% so far."

The discussion on Ultragenyx Pharmaceutical (RARE) centers on a significant 13% rebound following a record low due to a study failure, with commentary suggesting potential recovery into next year despite a 47% decline year-to-date.

Molina Healthcare Turnaround Uncertainty

"Well, Vonnie, you called out Molina Healthcare. This is the best performing stock in the S&P 500. That's ticker MH. Of course, we've been watching the stock because it is charging higher, up as much as 4.8% today. That is the highest level since October. This, of course, is after Michael Bur took the Substack. We're still hearing from Michael Bur. People have all eyes and ears listening to him. He essentially is saying that he's long the stock. He says that Molina seems best positioned to emerge stronger as a cycle turns, especially as it relates to its peers. I'm looking at shares of Molina Healthcare though down about 41% year to date. So, we'll just have to see whether or not this stock is able to chart some sort of turnaround story."

The speaker highlights Molina Healthcare (MH) as the top performer in the S&P 500 with a significant short-term gain, yet notes concerns with a 41% year-to-date decline, leaving its turnaround potential uncertain.

ON24 Acquisition and Premium Dynamics

"The ticker is shares are up by 37% today. Uh so the company uh agreed to be bought by Cvent. This is a software business for a total consideration of about $400 million in cash and this price represents about more than 60% of uh premium over the closing price on November uh November 10 actually. So the those companies expect to close this transa transaction in the second half of 2026. Goldman Sachs is an exclusive financier and then again when the company published earnings in early November they already said that they see some offers of a potential acquisition. Uh it is an unprofitable business. When you look at FA function on Bloomberg terminal it says that revenue is declining but losses are kind of narrowing. So that's that's the deal."

ON24 is trading with significant momentum, up by 37% due to an announced acquisition by Cvent at a 60% premium over a previous close. The deal, expected to close in the second half of 2026, highlights the market's reaction despite the company being unprofitable and experiencing declining revenue, though losses are narrowing.

FT Aviation's Innovative Shift to Data Center Power

"Yeah. So shares are up by almost 10%. This is an airspace company. It uh producers um aircraft leasing and engine leasing as well. So the company started a program to convert some of its engines to turbines basically providing power for data centers. So the production is expected to begin in 2026. I don't know how often you see companies from aerospace company uh sector providing power to data centers but this is a this is an interesting move."

FT Aviation (ticker: FTAI) is making a strategic move by converting engines into turbines to power data centers, an unusual initiative from an aerospace firm. Production is slated to start in 2026, presenting a long-term opportunity, with shares already up by about 10%.

Shake Shack's Stagnant Performance vs. World Cup Upside

"Um Shake Shack obviously delicious. I sometimes stop there and get myself a smoke shack. Um, but the stock hasn't budged in 5 years and this year it's down like 40%. Natalia, what's the problem with this purveyor of delicious hamburgers and hot dogs? ... However, I should say that some analysts see an upside because the company could benefit from the World Cup."

The discussion around Shake Shack reveals mixed sentiments. While the stock has shown stagnation over five years and experienced a 40% decline this year, there is a note that some analysts believe the upcoming World Cup could serve as a near-term catalyst for improvement, suggesting a potential short-term rebound despite the current downturn.

Molina Healthcare Positioned for Long-Term Upside

"Molina is looking to make money in Medicaid in 2026 while most of its competition loses money and it seems best positioned to emerge stronger as the cycle turns. Uh also he said that Molina could become a target of uh an acquisition if it remains as cheap as it is right now."

Michael Bur highlights Molina Healthcare's strong expense ratios and underwriting results, noting its ability to profit from Medicaid in 2026 relative to its competitors. He also mentions acquisition potential if the stock remains attractively priced, drawing an analogy to Buffett's GEICO purchase, which signals a bullish outlook.

Software Services Facing AI Disruption

"Software services are going to get eaten by AI. [laughter] True. You know, that's what I think. I could be wrong. I could be wrong because I've noticed lately um really access to data is a huge is a huge point, you know, because I'm always looking for cars in the aftermarket and I look on autotrader and I look at car gurus and I look at cars.com and when I use chat GPT or Google Gemini, it's useless. It's absolutely powerless. And even the AI bots will say, "Hey, listen. We don't have any access to the data.""

The speaker expresses a bearish macro view on the broader software services sector, suggesting that many firms will be disrupted by AI due to insufficient access to critical data. The commentary notes that companies with unique datasets, like Gong, might be better positioned despite the overall threat from AI-driven competitors.

Tesla Shifts Focus From Cars to Narrative

"Tesla nobody cares about cars anymore. And he's s he being Elon Musk has successfully diverted investor attention away from the bending metal to more of the story side of the game. The >> they could stop they could stop producing cars. Who cares? It's a $1.5 trillion company. If you add Ford's market cap plus GM plus Toyota plus Volkswagen plus Ferrari plus Koig's Egg plus Yugo, like every single car maker in the world, they don't equal this market cap."

The speaker minimizes Tesla's reliance on its core automotive business, suggesting that investor interest is now driven by its overarching narrative and massive market cap rather than traditional car production. This commentary places Tesla's brand and story above its underlying product fundamentals.

Tesla Q4 Vehicle Delivery Caution

"Tesla, let's go there. They have published a compilation of analyst estimates for vehicle deliveries to its website. By Tesla's count, analysts on average expect the company to deliver over 422,000 cars in the fourth quarter, which is down about 15% from the year earlier. It compares with the Bloomberg compiled average of 445,000 vehicles, and the average estimate for 1.6 million deliveries this year is down more than 8% from the year earlier period. Tesla even saw its shares plunge earlier in the year during production line retooling for the redesigned Model Y."

Tesla's delivery estimates for Q4 show a notable decline compared to previous periods, with expectations around 422,000 vehicles and a year-over-year drop of 15%. This comes amid production line adjustments and retooling for the redesigned Model Y, suggesting near-term headwinds for the company.

Meta Platforms' Strategic AI Acquisition

"Meta Platforms has agreed to buy Manis. It's based in Singapore. It's an artificial intelligence agent with Chinese roots. The deal right now values Manis at some $2 billion and it's a pretty rare US acquisition of an Asian tech company. This is a latest multi-billion dollar AI bet from Zuckerberg. The agreement was struck in only about 10 days. What Meta plans to do is to continue operating and selling the MANA service while also integrating it into its own products."

Meta Platforms is acquiring the AI startup Manis for $2 billion as part of a broader strategy to boost its AI capabilities. This acquisition underscores Zuckerberg's aggressive investment in AI and signals potential long-term integration benefits.

Meta's Acquisition Raises Questions on AI Spending

"Interesting acquisition from Meta. Now I have to note it's not having much reaction on the share price, but that's kind of interesting in itself. We have seen these recent AI acquisitions really lead to uh more excitement about stocks this year. It seems like maybe perhaps the market is now starting to doubt whether the spending is worth it. Meta has announced uh it will acquire a startup called Manis for $2 billion in a bet on AI agents. We're seeing shares of Meta just down 210 of 1%. They are underperforming the Mag 7. So again, maybe this is just another signal uh that the market wants in some way these tech companies to start justifying this gargantuan AI spending. But the really interesting thing about this, John, is that Manis is essentially a Chinese tech company. It was hailed as the next Deep Seek. It's really interesting to see a US tech company acquire a company with Chinese roots and whether that becomes a flash point in US China relations."

The commentary discusses Meta's $2 billion acquisition of the startup Manis as a strategic move in the AI space, while noting that the market reaction has been muted. The analysis raises concerns over whether the heavy spending on AI can be justified and hints at potential geopolitical ramifications given Manis' Chinese origins.

Tesla Shows a Rebound Amid Recent Weakness

"Uh look, we are seeing shares of Tesla rebound this morning. Uh they're up just shy of 1% which I know doesn't sound like a heck of a lot of movement, but yesterday it slid nearly 3.3% on essentially not a lot of new news. Um we had a lot of weakness uh in tech names yesterday. Tesla seemed to take a big of a brunt of it."

Valerie Titel highlights that Tesla is rebounding this morning after a significant decline yesterday amid a broader weakness in tech stocks. The commentary underscores that while the rebound is modest, Tesla's performance stands out in a challenging environment.

Rheinmetall Leads Defense Sector Rally

"Yes, despite kind of ups and downs uh in recent weeks for defense stocks, Ryan Metal remains the best performer on the DAX index this year and it is a big part of the reason why that index is set for its biggest annual gain in six years. So there is continued enthusiasm for that company which kind of regardless of what happens with the Ukraine peace process is set to continue to really benefit uh from Germany's plans to spend billions on on defense and infrastructure. Um to kind of zone back in on on today we are seeing how those Ukraine peace talks are feeding into that stock performance for Ryan Matau. Um yesterday we saw that stock down uh because Trump was saying that a lot of progress had been made on peace talks. But then today uh it's up because those talks are facing fresh fresh challenges with uh with Putin saying that Ukrainian drones had targeted his residents and saying that he would revise um his negotiating position as a result. And so that is leading to some of those defense stocks being higher this morning including Rangar."

The insight discusses how Rheinmetall is driving the DAX defense sector rally, supported by strong government defense spending and evolving Ukraine peace talks. The commentary notes that despite short-term volatility, the company's robust performance is helping the index set its best annual gain in six years.

Vistry Group Faces Housing Market Headwinds

"Yes, service through a house builder that it's seeing a bit of weakness and usually we uh that weakness in in house builders happens when we get data about the troubled housing market in the UK and today we got some data from Lloyds about uh the commuter towns around London seeing the biggest drop in house prices in 2025. So we're talking about um £35,000 being wiped off the valuation of the average home in a community commuter town like Crawley for example. Um so this really exemplifies that big gap that we are seeing that widening gap between the housing market in and around London which is the most expensive in the country of course um and and the rest of of the UK. So house prices and the growth in house prices is actually doing quite well in places like Scotland and and Yorkshire and Plymouth. Plymouth was actually the one where the house price growth was the strongest uh but not in London and not in the areas around London either. And that is a problem uh for housebuilders because it really shows kind of the magnitude of the challenges that they're facing despite all the planning reform and and the efforts from the government to to try and and get the that housing market back on track."

The discussion on Vistry Group outlines challenges in the UK housing market, highlighting a significant drop in home valuations in certain commuter towns as indicated by Lloyds data. The commentary underscores the widening disparity between London and other regions, reflecting potential headwinds for the housebuilder.

Glencore Benefits from Copper Rally

"Yeah, absolutely. So, we were talking yesterday about how good it is to be a kind of a gold and silver miner because of those precious metals rallying, but it's also great to be a copper miner like Glenorg because as you said, copper is seeing that major rally and it is headed for its longest winning run since 2017. Um, and that is because there are growing concerns around the supply chain for copper. There's been quite a lot of disruptions in some big copper mines this year and this really tight supply comes at a time when copper is in really high demand because it's a crucial material for a bunch of different things. We're talking about smartphones, fridges, electric vehicles, power grids, etc. But it's also really essential for data centers and of course that is going to be very important heading into next year as well. So we have this supply and demand dynamic that is fueling that rally and Glenor is a big beneficiary of that and we have seen uh shares rising this morning as that rally continues. So one to watch throughout the trading session today as well."

The commentary highlights Glencore's potential upside driven by a robust copper rally amid supply chain disruptions, noting that strong demand from various industries is supporting the stock. The speaker emphasizes that Glencore is currently benefitting from these tailwinds and is a stock to watch during today's trading session.

Digital Bridge's SoftBank Acquisition Sparks Mixed Reactions

"Don't talk about this one a lot. Ticker is DBRG, Digital Bridge, but it's definitely moving in today's session. We were seeing it earlier up for double digit gains. Now, it's about up about 9.8%. This is a data center company. Uh, and essentially, we did hear that SoftBank is buying the company for about $3 billion. This is a 65% premium to Digital Bridge's closing share price earlier this month back on December 4th. So, this transaction is expected to close in the second half of next year pending regulatory approvals. But clearly, you are seeing the stock getting a pop here. Shares are up about 36% so far this year. But Raymond James though, they're saying that they call this deal quote unquote underwhelming in terms of the deal price."

Digital Bridge (DBRG) is experiencing a significant move in response to SoftBank's $3 billion acquisition offer, which represents a 65% premium over its recent closing price. The deal, expected to close in the second half of next year pending regulatory approvals, has driven the stock up nearly 10% in the current session and 36% year-to-date, although Raymond James criticizes the deal price as underwhelming.

Digital Bridge Share Surge Amid M&A Activity

"Oh, for sure. And what is today's Monday, right? So, we could say M&A Monday perhaps. Looking at shares of Digital Bridge. This is actually a company I had to look into. This is ticker DBRG. Uh it's about $2.7 billion in market cap. We're seeing shares surging as much as 10% for double digit gains. This is the highest level we've seen for the company since October of last year. This is after SoftBank Group agreed to pay for um the company. Here we are seeing that Raymond Jane's analysts are saying that they called the valuation quote unquote underwhelming for this deal. But you are clearly seeing the street taking a liking to this at least if you look at the share performance for this company in particular. Shares up about 9.7 right now. But on a year-to-date basis we've seen the stock gain about 35%."

The speaker discusses Digital Bridge (DBRG) amid an active M&A environment, noting that the company's shares are surging up to 10%—a high not seen since last October—following SoftBank Group's involvement. While some analysts describe the valuation as 'underwhelming,' the market's strong reaction, with a nearly 10% intraday rise and a 35% year-to-date gain, underscores the positive sentiment.

Lululemon Turnaround Story in Focus

"Yeah, it's interesting because if you look at shares of Lululemon, that's ticker LU. We're seeing shares that are down 45% so far this year. It's a brand that's really been struggling in terms of getting broad-based reception, but we are seeing shares pointing a touch higher. Shares are up as much as 1.8% today in trading. And this is after its founder, Chip Wilson, as you mentioned, is pushing for changes to the board before they select a new CEO. So, we're all in following this story as we continue to see whether or not Lululemon is actually able to flush out some sort of turnaround story."

The speaker highlights that Lululemon (LU) has suffered a significant decline of 45% year-to-date but is showing early signs of recovery, with shares rising by 1.8% on the day. The founder's aggressive board changes signal a potential turnaround, prompting the speaker to follow the story closely for future improvements.

Lululemon Faces Activist-Led Board Shake-Up

"If you're looking at Lululemon, what swings we are seeing being taken by the founder of the business, Chip Wilson. He is launching a proxy fight at the retailer in an effort to remake the company's board as they wait for a new CEO. Wilson has nominated three director candidates to the company's board. According to sources, the nominees are executives from On Running, ESPN, and Activision. He still remains Lulu's second biggest shareholder with a nearly 9% stake in the company. He also reportedly isn't really trying to put himself back on the board, just trying to have some say in the future of the company. And it is rare to see a founder of a company turning to a hostile approach in the way that he is right now."

The discussion details Chip Wilson's aggressive move to influence Lululemon's board through a proxy fight, signaling potential instability as the company awaits new leadership. This activist maneuver may lead to significant changes in governance and strategy for the retailer.

Praxis Precision Medicine Surges on FDA Breakthrough Recognition

"So can always count on biotech companies to show some outsized moves and one of them is Praxis Precision Medicine. That is ticker PRAX. It soared as much as 18% today to breach the highest intraday level since 2021. This is a biotech company that received a breakthrough therapy designation by the FDA for treatment of patients with essential tremor. Piper Sandler analysts say that they notched another major win with this development. They believe that Praxis is positioned for a monumental 2026."

The segment underscores a significant surge in PRAX, driven by its breakthrough therapy designation and strong analyst support, suggesting considerable upside potential into 2026. The achievement marks a critical catalyst for the company in the biotech space.

Novo Nordisk's Downturn Amid Pricing Cuts and Patent Worries

"What's it doing today? Yeah, a company that was a big winner and has now turned into a loser. Unfortunately, it cut the listing price of its obesity drug WGOI by half in some parts of China. The Danish drug maker is getting ready for a potential flood of copycats as its semiglutide patent nears expiration. And it is now down 40% year to date."

The commentary highlights Novo Nordisk's recent struggles following a sharp price cut of its obesity drug in China and looming patent expiration, resulting in a significant 40% decline year to date. These factors combined indicate mounting competitive and regulatory pressures.

First Majestic Silver Under Pressure as Silver Rally May Be Ending

"Uh, Idaho is a big area for for silver. Um, but silver miners are on a back foot after the air, I guess, is starting to come out of this silver rally. So, we have the likes of Core Mining uh down [snorts] nearly 5%, Hela Mining down 4%, First Majestic Silver, ticker AG, funny for for those who know the periodic table, is down 4% as well. there. Um, you know, the silver's rally has really been led by this tightness of inventories and a lot of these silver miners have benefited from the runup of the price of silver in December, but it does seem to be like the that the rally might be ending for some of these silver silver miners headed into your end."

The commentary highlights that First Majestic Silver (ticker AG) and other silver miners are showing weakness with declines around 4-5%. The speaker notes that the recent silver rally, driven by tight inventories, may be coming to an end, suggesting potential near-term downside risks for these stocks.

Biogaya Shares Boosted by Analyst Price Target Upgrade

"Yeah, so that's not a company I've heard of before actually, but they make probiotic supplements for things like gut health and and immunity, things like that. This is of course something that is kind of all the rage at the moment, part of that broader wellness boom with everyone caring a lot about their protein intake and gut biome and and all of that. You haven't gotten it from Turkey over the past week. Yeah, [laughter] exactly. Um but Bay is up this morning after DNB Carnegie raised the price price target on that stock. Um and said that they could see margins recover quite a lot in 2026 and they expect a really strong sales growth uh for that and the end of this year for for the fourth quarter and then that momentum for earnings to continue to be really strong next year. So all around there's really good news for Baya and this vote of confidence has boosted those shares this morning."

Biogaya, a biotech firm that produces probiotic supplements, is receiving a boost after DNB Carnegie raised its price target on the stock. The analyst highlighted potential margin recovery in 2026 and strong sales growth in Q4, with continued earnings momentum expected into next year, offering a catalyst for further upside.

IPF Acquisition Commentary

"Yeah, so M&A doesn't really stop for Christmas. So, we had some bankers working over the last week. Um, the US-based uh direct lending company Base Point Capital uh has announced that it is acquiring IPF uh this morning. So, IPF is uh a consumer loan provider and it operates primarily in Eastern Europe and in Mexico. Um and the deal is valuing the company at 400 no sorry543 million. Um so this follows a courtship over the last few months. We had an initial approach in July, another in September, and then in November, Baspoint added a dividend payment to its proposal. And so that seemed to have sweetened the deal enough that IPF accepted. Um, and investors seem quite happy with the IPF's future as part of Base Point, and we have got those shares up quite strongly [music] this morning on the back of of that late December."

Kloe Mele outlines the acquisition of IPF by Base Point Capital, highlighting the extended courtship process including multiple approaches and the addition of a dividend payment that swayed IPF into accepting the deal. The commentary notes that investor sentiment is positive, as evidenced by the strong movement in the shares this morning.

Nvidia's Strategic Licensing Move Bolsters Its Competitive Edge

"Yeah, so Nvidia is also up by 53% on the weekly basis and this is the biggest gain since uh early October. So today we've learned that uh Nvidia um is up after the chipmaker agreed to a licensing deal with the AI startup Gro. Analysts are really positive on this news. Uh so the company uh paid for the right to use Gro's technology and will integrate its chip design into future products. Some of the startup executives are leaving to join Nvidia to help with that effort. Grock meanwhile will continue as an independent company with a new CEO. The deal has received multiple uh positive I would say um commentaries from Wall Street analysts. For example, Bernstein is saying that the move appears strategic in nature for Nvidia as they leverage their increasingly powerful balance sheet to maintain dominance in key assets. But it also seems to be more like a grab for technology and human capital by Nvidia rather than straight purchase."

The insight outlines Nvidia's recent licensing deal with AI startup Gro, viewed very positively by analysts including Bernstein. It emphasizes that Nvidia is leveraging its strong balance sheet to secure both technology and human capital, a strategic move that could further consolidate its market dominance.

Target: Activist Investment Amid Struggles

"Right. So, the Target, the ticker is TGT. Uh shares are up by uh 2.7% today after Financial Times reported that an activist investor built a stake in the big box retailer. Uh they citing people familiar with the matter. The FT said that Tom's Capital Investment Management made a significant investment in Target without disclosing any details. Uh in response to this request for a comment, Target said that it maintains quote a regular dialogue with investment community and it has a priority to get back to growth. Anyway, despite this gain today, we see that the stock is down by almost 30% on a year-to-day basis."

The report on Target (TGT) highlights that the stock experienced a modest uptick of 2.7% due to news of an activist investor building a stake in the company, even as the stock remains down roughly 30% year-to-date. Target emphasizes maintaining regular dialogue with the investment community and a focus on growth amid mixed market performance.

Sable Offshore: Regulatory Risk Impact

"So, we have this uh news development. So on December 23rd, the stock jumped by almost 37% after US regulators issued an emergency special permit for a part of that contested California pipeline which would pave the way for Sable Offshore to begin pumping pumping crude uh at its offshore oil rigs. But today we got news that environmental defense center and center for biological diversity filed an emergency motion to hold the res uh restart of this contested California pipeline. Environmental groups are saying that restarting the pipeline would invite invite another oil disaster on the central coast. So that is why the stock is down by almost 13% today. And again, this is still in process and we may hear more news uh maybe early next year or maybe even next week."

The analysis on Sable Offshore (S) explains that after a regulatory permit boosted the stock significantly in December, new environmental motions are now threatening a restart of the pipeline, citing potential disaster risks. The pending regulatory actions have driven the stock down by almost 13%, with further news expected soon.

Warner Bros. Discovery: Pending Litigation Catalyst

"So, the stock is down by 1.4% today uh after reports from the New York Post saying that Paramount Skyans could walk away from its 30 per share cash bid and instead it could litigate against the company's uh board for how it handled the process. People inside Paramount's guidance uh told the New York Post that uh they want to allege that directors and management ignored their uh six allcash uh offer uh for the company and actually favored Netflix's cash stock bits throughout the bidding process. But um as of now we are still waiting and we have time until late January uh until investors would make a decision. And what I read between the lines on this is while we've got a weekend coming up for a lot of people, I'm betting that the bankers are going to be working over the weekend for any developments come Monday."

The commentary outlines the situation with Warner Bros. Discovery (WBD) where the stock is down due to reports that a potential cash bid may be challenged legally, with management possibly favoring an alternative proposal. The analyst indicates that while investors await a decision until late January, there may be weekend developments from banking channels.

Biohaven navigates mixed clinical trial results amid upcoming data

"Yeah, really incredible move for this company in today's trading session. In the pre-market, it was down something like 12% and now it's up just slightly. It was sinking earlier after a mid-stage study of the company's experimental drug BHV7,000 for the treatment of major depressive disorder missed its primary end point. City said that the data were disappointing, but investors had very low expectations of the study working. According to analyst Samantha Semancow, investors have been more focused on the upcoming latestage epilepsy study data for this company. So that probably made it really easy to kind of shrug off that disappointing study result. The company does not plan on any additional psychiatric clinical trials into 2026."

Biohaven experienced volatile trading after its experimental drug missed a primary endpoint, but investor focus has shifted to upcoming late-stage epilepsy data, with plans for no additional psychiatric trials until 2026.

Nvidia leverages AI startup deal for strategic advantage

"So, of course, we do have to start with the world's largest publicly traded company. It is up about 1.3% right now after the company agreed to a licensing deal with AI startup Gro. Uh the company has paid for the right to use Gro's technology and will integrate its chip design into its future products. really interesting some of the moves that will happen around this arrangement. Some of the startups executives are leaving to join Nvidia to help with this effort and Grock will continue as an independent company with a new CEO. Obviously, investors are liking this deal given the stock reaction, but I also like to read off some of the Wall Street analyst commentary. Bernstein said that the move appears strategic in nature for Nvidia as they leverage their increasingly powerful balance sheet to maintain dominance in key areas. And then Caner Fitzgerald says that the news offers both offense and def defense and only enhances Nvidia's full system stack."

Nvidia's licensing deal with AI startup Gro is seen as a strategic move to enhance its chip design capabilities and market dominance, with supportive analyst commentary reinforcing investor confidence.

Negative Outlook on Biohaven's Experimental Drug Study

"And let's wrap up Alexis with Biohaven based in Connecticut. Following this morning in premarket trading, they had a mid-stage study of the company's experimental drug for the treatment of major depressive disorder. It missed the primary endpoint. So that's not good. That is not good. Sounds like it's not working. Well, back to the drawing table."

The commentary highlights that Biohaven's mid-stage study for its experimental drug missed its primary endpoint, sparking repeated negative reactions which indicate that the treatment approach is not working. This serves as a negative catalyst and suggests caution for investors considering the stock.

Biohaven's study miss triggers share drop; future focus on alternative therapies

"Biohaven shares drop 14%. um they're in the healthcare industry. So shares are slumping because um a mid-stage study of the company's experimental drug for the treatment of major depressive disorder missed the primary endpoint. So City said the data was disappointing. They had a buy rating, but investors had quote very low expectations of the study working. Raymon James, who also had a buy rating, said that investors should stay focused on the focal epilepsy opportunity. And RBC said that the trial miss could be a clearing event, so to speak."

The speaker explains that Biohaven (BHVN) experienced a sharp 14% drop in shares after its experimental drug missed a primary endpoint. Despite previous buy ratings, the market's low expectations suggest that the company may shift its focus to other therapeutic areas like epilepsy, reflecting immediate investor concerns.

Sidus Space advances in defense sector with contract award

"Citus space. I thought it was Citus and then I listened to a video and it said Citus when the video was introducing the CEO. So, ticker is SIDU. It's up a tenth of 1%. This is a space and defense technology company. So, there are two developments there. They recently announced plans to offer to sell shares of their common class A common stock in a proposed public offering at 1.30 a share. And last week, the company was named a contract awardee on the missile defense agency's shield IDIQ program."

The speaker discusses Sidus Space (SIDU), noting its upcoming public offering and its recent contract win with the missile defense agency, providing mixed signals as the stock has rallied significantly yet faces dilution risk from the offering.

Nvidia licensing deal advances AI capabilities

"Let's start with uh one of our favorite stocks here because it's always uh the most active. Nvidia in the pre-market. >> Nvidia. Yes, this is a favorite. It's higher by maybe 510 of 1% in pre-market trading. So they agreed to a licensing deal with AI startup Gro. So this furthers Nvidia's investments in companies connected to the AI boom. So the chipmaker as we know has paid for the right to use Gro's technology and will integrate its chip design into future products."

The speaker highlights Nvidia's strategic licensing deal with AI startup Gro to enhance its chip technology and maintain its leadership in the AI space, underscoring Nvidia's continued focus on integrating advanced AI solutions into its product offerings.

Nike Company Commentary on Earnings Pressure and Insider Buying

"Let's start with Nike. The ticker is N K E. Uh shares are up by almost 5% after the filing showed that Apple CEO Tim Cook bought almost three million uh dollars worth of shares on December 22nd. Uh Tim Cook, he's Nike's lead independent director. So he made this move actually uh the next day after the stock tumbled by 10.5% on disappointing earnings report. So Nike shares have been under pressure. The latest earnings release showed that sales in China are really under pressure, down by 17% last quarter, and also the company expects a decline in sales this quarter. So again shares are down by 20% this year but for Tim Cook that was a buying opportunity."

The commentary centers on Nike's recent earnings challenges, including a 10.5% drop and weak sales in China, yet highlights insider buying by Tim Cook as a potential signal of undervaluation. This insight provides investor color on how internal confidence might contrast with broader market concerns.

Costco Upgrade Trade Call with $1100 Price Target

+11.00%current return

"Costco the ticker is uh CO shares are up by 2% today. It came after an upgrade from an analyst from North Coast Research. Now, he uh upgraded the stock to buy from neutral. Now, he set the sets the price target for 12 months at $1,100. Now, it's trading at almost $880. So, it's a pretty big move. It implies almost a 30% gain from uh the last price."

The analyst upgrade on Costco, with a 12-month price target of 1100 and current trading near 880, indicates a strong trade call, suggesting a nearly 30% upside. The commentary highlights the stock's undervalued condition despite short-term struggles, emphasizing a medium-term buying opportunity.

Snowflake's Strategic Move to Boost Competitive Edge

"It is snowflake. The ticker is snow. Uh shares are down by 2.3% today. It came after the information reported that the software company is in conversations to buy a startup clo uh called observe for about $1 billion. So observe uh this is a startup based in California and it develops the so-called observatory tools that help developers to track how their apps perform or if there are any challenges on the software uh side. And analysts are really excited actually about this potential deal because they say it will u allow the company to compete more closely with companies like data bricks. So for now it is a pretty solid move. However, of course shares are down."

Snowflake (SNOW) is reportedly in discussions to acquire a startup for approximately $1 billion, a move that analysts believe could enhance its competitive positioning against rivals like Databricks. Despite a slight drop in share price, the acquisition is viewed as a solid strategic step to bolster its offerings.

Dynavax Acquisition Premium Sparks Optimism

"Exactly. So the ticker is DVAX shares are up by 38%. It came after Sani, which is a French pharmaceutical company said that it will start a cash tender to offer to acquire all outstanding shares of vaccine maker for $15 per share. So agreed to buy Davox for about $2.2 billion. This deal gives Sani access to some vaccines including hepatitis B vaccines and we know that this is also quite a crucial deal for Sanophi because it's struggling also um to increase performance and to boost its revenue as we see lots of challenges in global vaccine market."

The commentary focuses on Dynavax (DVAX) where acquisition news has driven shares up significantly. The tender offer at $15 per share by a French pharmaceutical company is viewed as a strategic move to enhance vaccine access and improve revenue performance amid global market challenges.

Intel's 18A Tech Issue Casts Doubt on Turnaround

"Let's start with Intel. The ticker is INTC. Uh the shares are down by almost 2%. So it came after Reuters reported that Nvidia halted test that uses um Intel's uh 18A technology to produce its chips. We know that recently Nvidia reported that uh it tested actually if it could manufacture its own chips using this 18A production technology. Uh Reuters uh cited people familiar with the matter. As of now, uh both companies did not comment on that and it's been really critical for in Intel's turnaround story. So, investors really want to see if this uh story can play out."

The speaker highlights concerns regarding Intel's 18A production technology after Nvidia halted its testing, casting uncertainty on Intel's turnaround prospects. Investors appear to be wary as they await further developments in this story.

Uipath Index Upgrade Boosts Shares

"And then finally, we have application software maker Uipath, its ticker party. Their shares are jumping about 8%. And the reason for that is it's set to replace Synovus Financial in the S&P MidCap 400 index."

The commentary notes an 8% jump in Uipath's shares, attributing the rise to the company's impending replacement of Synovus Financial in the S&P MidCap 400 index. This index upgrade is hinted as a catalyst for the stock's recent performance.

AC Space Mobile's Satellite Launch as a Competitive Catalyst

"AC Space Mobile, its ticker, AC. Yes. Their share has been up as much as 7%. It launched its largest ever satellite from India. Now, this is the first in a series. They're going to have a number of deployments, but it's really trying to compete against Elon Musk, Space X, right? It delivers this space based connectivity to mobile phones. So that's why this is big news for them, because it kind of ups the competition in that space."

The insight focuses on AC Space Mobile's recent satellite launch from India and notes a 7% share increase. The speaker emphasizes that this marks the first in a planned series of deployments aimed at challenging established players like SpaceX in providing space-based mobile connectivity.

Insider Activity at Nike Signals Confidence Amid Weakness

"Nike up as much as 2%. The reason for this is there's a filing that shows that Apple CEO Tim Cook purchased $2.95 million worth of shares on Monday. Now, if you remember Friday, Nike shares dropped 11%. They warned of the sales decline, the current quarter weakness in China, weakness in his Converse brand. And then what does Coke have to do with Nike? You're kind of trying to figure it. Cook is actually Nike's lead independent director. He's served as director since 2005, but the filing shows he purchased 50,000 Class B common stock weighted average price of $58.97. So he now owns just over 105,000 shares in Nike."

The discussion centers on Nike's modest 2% rise following a significant insider move by Tim Cook, who, despite a previous drop of 11%, increased his stake in the company. This move is highlighted against a backdrop of sales cautions in China and brand-specific weaknesses, suggesting a nuanced signal regarding Nike's short-term dynamics.

Intel's Production Process and Share Decline

"To start with Intel. I've been hitting it all and all morning long I antsy. The shares have been down as much as 3%. The reason why? Well, Reuters is reporting that Nvidia stopped the test to use Intel's production process to make their advanced chips and NVIDIA tested the so-called 18 a process, but it just didn't move forward with it. So Intel, they recently opened this new factory in Arizona. It's known as Fab 52, and it's the first to go into mass production with this kind of technique. So Intel says it's the most advanced chip production technology developed and deployed in the U.S. I'm not sure why in backed out of it."

The commentary highlights Intel's recent production move with its new Fab 52 facility and notes that shares have dipped 3% after Nvidia halted its test of Intel's advanced production process. The speaker expresses uncertainty over Intel's decision-making amid competitive pressures, emphasizing the U.S. push for advanced chip technology.

Dynavax's Acquisition Deal Sparks Positive Reassessment

"Yes. Okay. So, Dynavax Technologies up as much as 39%. Um, they had a 13% drop so far this year. So, this is pretty some good news. Uh, good news for them. It's DVAX. Uh, French drug maker Sanify. Uh, Santa, yeah, they agreed to buy the company for about $2.2 billion. Um, so Sani, they're they're looking to expand. They have the vaccine business. You've probably seen the commercials for their flu shot franchise. Um, Dynavax, this deal gives them a hepatitis B vaccine that's already kind of marketed in the US. It also gives them an experimental shingle shot. So, they're they're trying to kind of up their their game. Um, it CEO has been investing in research development M&A deals. He's looking for alternative revenue streams to kind of replace their top selling mel medicine which is dupixent and that is facing a patent cliff and that's the reason for that. Um, but it came after you know just minutes. Um, Santa Fe said the US Food and Drug Administration rejected its experimental multiple scerosis drug. So, this kind of was the news on the back of that."

The speaker highlights Dynavax (DVAX) experiencing a substantial rebound of 39% amid acquisition news. The commentary details how the deal with French drug maker Sanify for approximately $2.2 billion provides Dynavax with a marketed hepatitis B vaccine and an experimental shingles shot. The narrative also mentions the CEO's strategy to diversify revenue streams as its top product faces a patent cliff, suggesting near-term positive catalysts following the acquisition.

B&M Faces Turnaround Challenges Amid Weak Performance

"Yeah, so this is sadly the second worst performer in the stock 600 index. the shares B&M shares have more than half this year and it's on track for its worst year on record following also what was a pretty underwhelming 2024. So it's been a sort of series of unfortunate events. Um the company is grappling um with the higher cost of hiring and also rising competition from lower c cost rivals. It operates in the discount retailer segment and its main customers have also been grappling with the cost of living crisis. Its CFO has exited following an accounting error and it's also got a relatively new CEO who said that the turnaround could take up to 18 months."

B&M is struggling significantly, being the second worst performer in the stock 600 index this year. The company faces multiple headwinds including rising labor costs, intense competition, and a challenging cost-of-living environment for its core customers. With leadership changes, including the exit of its CFO and a new CEO warning of an 18-month turnaround period, investors are advised to monitor its recovery closely.

Abbyax's Positive Trial Results Drive 1600% Gains

"Yeah. So this is a French biotechnology company and biotech tends to be quite a binary bet for investors. So the these companies have uh drugs in development and either um the trial results are positive um and we see huge kind of rallies in the shares or they're negative and you can see very big falls. So Abbyax's shares are up more than 1,600% this year making it easily the top um performer in the stock 600 index basically because it got positive trial results for its bowel disease drug. Um so this is a positive development for the company."

Abbyax, a French biotech company, has experienced a staggering increase of more than 1,600% in its share price following positive trial results for its bowel disease drug. The success positions it as the top performer in the stock 600 index, with upcoming phase 3 maintenance results in the second quarter and additional trial news later in the year serving as key catalysts.

BP Divesting Castrol Stake

"So, it's been a busy few weeks of news flow for BP, the um the oil major. So, it's agreed to sell a majority stake in its Castrol business to Stone Peak Partners. So, this is part of its plans um to divest some of the assets from its portfolio. So, it will raise about 6 billion for a 65% stake in the group. and it looks like the deal is set to complete at the end of next year."

BP is restructuring by selling a majority stake in its Castrol business to raise approximately $6 billion. The divestiture, part of a strategic pivot back to fossil fuels after an unsuccessful renewable venture, is expected to complete at the end of next year. Investors are watching to see how the new CEO will steer the company moving forward.

Precious Metals Rally Amid Safe Haven Demand

"I mean, these metals have seen an absolutely stunning rally this year, and yeah, they're all at record highs today. So this really boosts the companies that get these metals out of the ground. So stocks like Frisilla up 420% this year. Hawk Tiled, Endeavor also way up over 100% this year. There's a lot of safe haven appeal for precious metals miners. And we're seeing tensions in Venezuela between the Ukraine and Russia which boosts the appeal of these kind of assets. And with copper, it's also just soaring. There's worries over tighter supply next year and also the metal is used in new technology especially in things like electrification and in data centers which are obviously key for powering the artificial intelligence. And so you know the basic resources sector, it's up about 26% this year in Europe and it's one of the top performing sectors."

The commentary highlights a strong rally in precious metals and associated mining stocks, driven by record highs and safe haven demand amid geopolitical tensions and supply concerns. The speaker notes significant gains in companies like Frisilla and Endeavor, and points to copper's demand from new technologies as a catalyst for continued sector strength.

BP Divestment Strategy Amid CEO Shakeup and Activism

"So, BP has agreed to sell a majority stake in its Castrol business to Stone Peak Partners. So Castrol it makes lubricants for autos and industries and it has also been developing a liquid cooling technology for use in AI data centers. So BP will raise around $6 billion for 65% stake in the group and it looks like the deal will be completed by the end of next year. So, it's been it's been a really busy year for BP as you mentioned. You know, they are replacing their CEO after just two years in the job and it's really come under pressure from an activist investor Elliot to pivot back towards fossil fuels after a not particularly successful foray into renewables."

BP is executing a significant divestiture of its Castrol business as part of a broader strategy to refocus on core oil and gas operations amid a troubled CEO tenure and activist pressure. The maneuver, expected to complete by the end of next year, aims to raise $6 billion. However, BP's shares have underperformed compared to the broader energy sector, indicating market skepticism regarding its strategic pivot.

Novo Nordisk Gains Momentum with US Pill Approval

"Yes, it is a very nice day for the company. The ticker is NVO. Shares are up by 7.3%. At one point, shares jumped by 10% which was the biggest jump since August 2023. Of course, it came after the company said that it won an approval to sell a pill version of its Begoi drug in the US. The company will start selling it here starting from January and analysts were really excited about this news. They say it gives the company a really big tailwind especially as competition kind of is going to be more severe for the market."

Novo Nordisk (NVO) experienced a significant intraday rally, boosted by regulatory approval to introduce a pill version of its drug in the US, with sales set to begin in January. Analysts view this approval as a tailwind, particularly important given increasing competition.

ServiceNow's Strategic Acquisition and Its Overhang

"Service Now biggest acquisition ever right and on a Tuesday we are seeing this on a Tuesday. We saw that they did reach a deal to buy cyber security startup uh Armis. This is a deal that's valued at about 7.75 billion. We know Service Now is an IT management company. Uh we are seeing this representing its largest acquisition to date. Service Now will pay in cash for this deal uh for Armis and it expects to fund the transaction through a combo of cash on hand as well as debt. So we're looking at shares that are down as much as 2.9% on the day."

The discussion on ServiceNow focuses on its largest acquisition to date of cybersecurity firm Armis for roughly 7.75 billion. Despite the strategic move, the stock is experiencing short-term weakness with shares down 2.9%, compounded by an overhang from recent share struggles. The deal, expected to close in the second half of 2026, presents both a long-term growth catalyst and near-term investor caution.

Legal Setback Weighing on Johnson & Johnson

"Johnson and Johnson, ticker J&J, it's down for a different reason. We are seeing shares falling as much as 2%. This is after the company was ordered to pay about 1.56 billion to a Maryland woman. Essentially, she blamed the company's talkbased baby powder for causing asbestous linked cancer. So jurors did find uh this in um for the woman. They did see two units of its staff and the spin-off Kin View of J&J. They were liable for failing to warn this woman about the fact that there was uh the baby powder was tainted with asbestous. So we are seeing shares that are down reacting just a touch down about 9/10en of a percent right now as we speak."

The commentary on Johnson & Johnson (J&J) centers on a significant legal judgment where the company was ordered to pay approximately 1.56 billion dollars, resulting in a modest decline in share price. The legal setback over its baby powder product and related liabilities is having an immediate, negative impact on the stock.

Nova Nordisk's Moment with Oral Pill Approval

"Clearly people are really interested in this oral pill that we know Nova Nordis just got approval in the US for this or the pill version of its obesity shot WGOI. This is really great news for Nova Nordisk, especially as we think about it in comparison to Eli Lilly, its competitor. Uh they essentially expect to get approval for their version of their oral pill by March. So, we've got Novo Nordis, ticker NVO, in ahead of Elley here. But, I mean, it really is a stock that's been struggling. I'm taking a look at shares of Nova Nordis on a year-to-date basis, down 41%. So, I think that this is really a strong important moment for this company, and you're definitely seeing shares uh clearly investors are liking this. Shares are up as much as 11%. That's the biggest jump we've seen on a single day basis since January for the stock."

The speaker highlights a major catalyst for Nova Nordisk (NVO) with its newly approved oral pill for obesity, contrasting it with competitor Eli Lilly's timeline. Despite being down 41% YTD, the stock experienced an 11% jump, signaling renewed investor interest and a potential near-term turnaround.

Huntington Gains with US Navy Warship Contract

"Let's take a look at Huntington, which is a ship builder. So, ticker HII currently shares up just a little bit, 0.2%, but yesterday was really the big rally. They were up more than 5% and it is enjoying a fourth straight day of gains all because of announcements from the US Navy. So, the Navy saying that it plans to build a new class of warship as part of President Donald Trump's Golden Fleet bid to revive US ship building. And so, Navy Secretary John Felen announcing the plan and they will aim to have the first boat ready by 2028. Guess which company is building it? Huntington. And the ship apparently will be based on Huntington's Legendass Cutter."

Christine Kino describes a notable rally in Huntington (HII) shares driven by a US Navy announcement to build a new class of warship, with the first vessel expected by 2028. This development underscores Huntington's role in benefiting from revived US shipbuilding efforts.

Albamarl Positioned for a Turnaround in Lithium Cycle

"Let's talk about Albamarl, which is I mean for the most part it is mainly a lithium producer, right? It's a chemicals company, but lithium is really its big thing and it seems like it's mostly gaining in sympathy with the rally in industrial metals that we're seeing today... And on the company specifically, we do have Bloomberg Intelligence weighing in on its fundamentals. So our analysts are saying that the company is adjusting its operating and cost structures to reflect a lower for longer price environment for lithium and so when the cycle turns and it seems like we are starting to get that turn now in industrial metals then it will be more competitively positioned so keep an eye on that one. Those shares at the moment, you know, ticker ALB are moving quite a bit, up 1.6% and up 71% year to date for the Charlotte, North Carolina based company."

Christine Kino highlights Albamarl's adjustment in operating and cost structures amid a prolonged lower price environment for lithium. With the industrial metals cycle showing signs of turning, the company may become more competitively positioned, supported by strong year-to-date gains.

Eli Lilly Outperforms as Novo Nordisk Sets Pill Launch

"Well, we got to take a look at Eli Lily today given the Nova Nordisk news. So, Eli Liy shares uh ticker ly and those shares just up a touch right now at the moment... But overall, Eli Liy still very much winning uh that raise when it comes to at least share moves this year. They have risen uh 39% versus Novo's 47% decline. But yeah, I mean the Novo uh US ability uh presence shall we say is certainly potential threat to Eli Lilly here."

Christine Kino discusses the competitive dynamics between Eli Lilly and Novo Nordisk, noting that while Novo is launching an obesity pill in early January, Eli Lilly's shares have risen 39% compared to Novo's 47% decline, suggesting a stronger market performance currently.

Huntington Ingalls Boosted by U.S. Navy Contract

"I want to take you to shares of ship maker, uh, Huntington Les Industries. Okay. This is ticker HI. Climbing as much as 4%. So, the company said it's going to build this new frigot for the US Navy, right? But this is a contract. It was already announced, but late yesterday it got a boost because President Trump announced this new Trump class of warships. Um, the CEO said that they're ready. They're looking forward to helping the Navy. It's going to be a good program. They have confidence in their ship building division. The cost, they didn't give a dollar amount for the contract. Um, but you know, Trump's been touting about he said their new ships are going to weigh like 30 40,000 tons. They're equipped with nuclear cruise missiles, hypersonic weapons, electric rail guns. Um, he said they're going to be made with steel instead of aluminum. Um, and they're going to create jobs. He says they could do it in two and a half years."

Huntington Ingalls Industries (HI) is highlighted as benefiting from renewed optimism after securing a U.S. Navy contract. The commentary emphasizes that a boost came after President Trump introduced a new Trump class of warships, with the company expressing readiness and confidence in its shipbuilding division. The discussion also notes significant capabilities in advanced weaponry and a projected delivery timeframe of two and a half years, positioning the company favorably amid government-driven defense investment.

Orsted Lease Suspension and Legal Option Commentary

"I want to take you to Orsted. Their shares have been down about 1% in Denmark. So the back story, the U.S. suspending the leases, right, of all five wind farms under construction off the East Coast. It's an industry that's been kind of targeted by the Trump administration. Maybe it's part of this attack on clean energy, but you have the U.S. Interior Department saying it's because of national security concerns. Orsted said it's considering all options, even legal action, to respond to that U.S. decision to suspend those leases for the Revolution, Wind, Sunrise, wind projects."

The speaker discusses Orsted's situation after the U.S. suspension of leases for its wind projects, attributing the move to national security concerns. Orsted is weighing its response options, including potential legal action, amid a broader political attack on clean energy. The commentary implies caution given the regulatory risks impacting near-term performance.

Huntington Ingalls Industries Contract Commentary

"I want to take you to shares of chipmaker Huntington Ingalls Industries. Okay. This is ticker H. I climbing as much as 4%. So the company said it's going to build this new frigate for the U.S. Navy. Right. But late yesterday it got a boost because President Trump announced this new Trump class of warships. Its CEO said that they're ready. They're looking forward to helping the Navy. It is a huge Navy thing. If you've ever been down to the Newport News, Norfolk area, you've seen huge shipbuilding footprints with Navy ships all over the place. He says it could do delivery in two and a half years."

The commentary focuses on Huntington Ingalls Industries, noting its recent 4% share climb tied to the new U.S. Navy frigate contract and positive remarks following Trump's announcement of a new warship class. The speaker underscores the company's robust position in a key Navy shipbuilding hub, with contract delivery expected in two and a half years.

Novo Nordisk Pill Approval Trade Call

+18.97%current return

"All right. Let's start with Novo Nordisk. Right. Their shares have been up as much as 8%. So the big thing, yes, it won the approval to sell that pill version of its we go we shot in the U.S. They expect to launch in early January, about $140, $149 a month. That's what it cost for that, starting to get a dose. But the company really needed the boost. I mean, the stock's nearly halved in value since the start of the year. Should I do this? Absolutely. Why not? I'm a little worried. I'm still worried about it."

The speaker highlights Novo Nordisk's recent approval to market its pill version, noting an anticipated product launch in early January as a potential catalyst, despite recent stock underperformance. The call is to take a position, though tempered by some caution.

Novo Nordisk Boost from Obesity Pill Approval

"That's right, 7% because I don't want the listeners to be in suspense. That's how much shares of Novo Nordisk are up after that approval to sell the pill version of its blockbuster obesity shot. People will be eating plenty at Christmas because the pill won't go in until early January, just in time for those New Year's resolutions. And the big part of this announcement is that they are getting a head start over their major competitor in the space, Eli Liy. They could get approval for their own competitor pill in March. So, this is really giving Novo Nordisk a boost towards the end of the year, a year where it could see some upside. It's down 44% this year because of losing out to Eli Liy, which is up 40% this year."

Novo Nordisk stock surged 7% on approval to sell a pill version of its blockbuster obesity treatment. The new approval provides the company with an early advantage over competitor Eli Liy, which may only get its own pill approval in March, offering a near-term upside catalyst for a stock that has lagged this year.

Novo Nordisk's Pill Approval as a Catalyst to Defend Market Share

"There is one stock in Europe that is really surging today and that is Novo Nordisk. Investors salivating over a a new drug, a new advance indeed. Yeah. Kind of the one big story before uh the Christmas little fully kicks in. Uh but as you say, yes. So Novo Nordisk has won approval to sell a pill version of its weavi uh blockbuster obesity drug that's in the US and sale should start in January. And the reason that this is really boosting shares, shares are up about 7% and they've been holding those gains all through the morning is because it's a a real crucial step to try and defend uh it's market share essentially from US rival Eli Liy."

Novo Nordisk has won regulatory approval to sell a pill version of its blockbuster obesity drug, slated to begin sales in January. This move is viewed as a crucial step to defend market share from its US competitor, with shares already up about 7% in early trading.

Pets at Home CEO Change Hints at Turnaround Opportunity

"Pets at home have a new top dog. I've been regaling everyone on the team because we have a new pet at home but not a dog. It's a cat. Anyway, pets at home. Tell me more. Uh yes, a new top dog. A new CEO. He's called James Bailey. He he comes from Waitros. Uh he was managing director at Waitrose. So it comes after um Pets at home obviously did very well during COVID and then this year particular have been struggling. They're in the middle of a turnaround. So hoping that the stock is rising on on this slightly so I guess there's a bit of hopes for renewal in 2026."

Pets at Home is undergoing a leadership change with the appointment of new CEO James Bailey from Waitrose. The company, which performed well during COVID but has struggled this year, is now seen as being in the midst of a turnaround, with hopes that this change will drive a stock recovery culminating in a renewal by 2026.

Orsted Faces Regulatory Headwinds in Wind Farm Projects

"So this is the latest of the Trump administration. It's been a tumultuous year between the Trump administration and the and the clean energy sector. And this was news yesterday. So it's a bit of a day two but the stock is continuing to react. So the US has suspended leases for all five wind farms that are under construction off the east coast of America and Bloomberg estimates put the total committed capital for those five wind farms at about 28 billion US. So it's big a big deal. Um this was so this was as I say was announced yesterday and they're citing national consu national security concerns. So as I say the industry has been kind of repeatedly targeted by the Trump administration. If you look at Orstead's share price in particular, it's it's been kind of up and down, slumping quite heavily on some of this news throughout the year."

Regulatory actions by the Trump administration have negatively impacted Orsted, with the US suspending leases on five offshore wind farms due to national security concerns. The commentary notes that repeated regulatory targeting has caused significant volatility in Orsted's share price, with recent news amplifying its downward trend.

Novo Nordisk's Pill Approval as a Growth Catalyst

"Nova Nordisk surging today, investors salivating because there's been a new step forward for this drug maker. Yeah, a real crucial step actually. So, they've they've won approval in the US to sell a pill version of uh Wiggoi, their their blockbuster obesity drug. So, that should start from January and it's it's at a starting price of 149 a month. But the reason it's crucial is is uh Novo essentially kind of created this whole market and then they've been struggling to keep up particularly in competition with their US rival Eli Liy. And if you look at their both of their share prices um over the past year or so, you can see a real divergence. So Eli Liy kind of shooting quite far higher and uh Novo has has had quite big losses really really this year. So they're trying to keep up. They're trying to stay competitive."

Novo Nordisk has received US approval to launch a pill version of its blockbuster obesity drug starting in January, aiming to revitalize growth amid stiff competition from its US rival Eli Liy. The commentary highlights a divergence in share performance over the past year, noting that although Novo created the market, it has lagged recently and is looking to use this launch as a growth catalyst.

Investors piling into Clearwater Analytics despite lower-than-expected deal price

"Right, Clearwater Analytics. Uh, we did see a group of private equity firms agreeing to buy this company. Uh, about $8.4 billion is the deal that we're talking about here, but analysts did say that this deal price was lower than anticipated, but if you think about how the street was really viewing this, we did see shares uh moving higher. So clearly investors are buying in on this, but analysts are saying, 'Hey, maybe this wasn't the right price that we were looking for.'"

The commentary highlights that Clearwater Analytics (CWN) is under acquisition for approximately $8.4 billion. Despite the deal price being lower than expected by analysts, investor interest remains strong as indicated by rising share prices. This creates a mixed sentiment with a note of caution on whether the price was optimal.

Bullish Trade Call for Navan with Attractive Price Target

+11.16%final return

"Yeah, so this is one of the post IPO stories. We saw that Navan, the ticker is NAVN, shares are up by five percent today after being added to the broad market Russell 3000 and small cap Russell 2000 indices. However, it's still down by more than 30% since its IPO in late October. What is interesting is that upon analyst initiation, people are very bullish on this stock. The price target is at around 25 and it's currently trading at 15. Wall Street remains optimistic, even though the company is not yet profitable and fundamentals still present uncertainty."

This insight presents a trade call for Navan (NAVN), noting that despite the stock's recent listing and index inclusion, it remains undervalued compared to the analyst-backed price target of 25 while trading at 15. The bullish sentiment from analysts combined with the post-IPO rebound suggests a potential upside trade despite some operational uncertainties.

First Solar Benefits from Intersect Partnership

"Yes. So, First Solar, the ticker is FISLR. Shares are up by 6.5%, one of the biggest and highest intraday moves since June 2024. This is after Alphabet agreed to buy clean energy developer Intersect Power. Of course, it will help the company to get more access to electricity. The reason why First Solar is up today is because Intersect, one of its biggest clients, is tied to a contract running from 2025 to 2029. So, it is a big beneficiary of this deal and trade right now."

The insight highlights First Solar (FISLR) as a primary beneficiary following Alphabet's acquisition of Intersect Power. With the longstanding contract from 2025 to 2029, the commentary underlines why the stock is experiencing significant intraday gains and suggests an actionable trading opportunity.

Warner Brothers Financing Guarantee and Shareholder Reaction

"Right. So let's start with the biggest uh one of the biggest movers today. Uh Wall Street uh Warner Brothers the ticker is WBD. Shares are up by four 3 almost 5% today. Uh as we know Larry Ellison who is a co-founder of Oracle and a father of David Ellison agreed to provide a personal irrevocable guarantee for this 40.4 billion dollars in equity financing for Paramount's bid for Warner Brothers. Basically, he agreed not to revoke his family trust while the deal has been pending, and Paramount has even increased the regulatory reverse termination fee. For now, the next stage is to wait and see how shareholders react, with time until January 21st."

This commentary reviews the recent financing guarantee provided by Larry Ellison for Paramount's bid for Warner Brothers (WBD) and emphasizes the pending shareholder reaction before any further move. The details surrounding the increased termination fee and the wait until January 21st provide context for potential trading adjustments.

Rocket Lab Secures Largest Contract to Date

"Rocket Labs, this is in the aerospace uh sector. We're looking at shares of Rocket Lab. This ticker RKB, they're up more than 8%. Uh the company won a contract to design and build 18 satellites. This is the company's largest single contract to date. So, we are seeing shares up about 8% but on a year-to-date basis, the stock has really been on a tear, almost up about 200%."

The speaker notes that Rocket Lab (RKB) has secured its largest contract yet—designing and building 18 satellites—resulting in an 8% immediate share increase and a strong year-to-date performance of nearly 200%. While the commentary is primarily observational, it underscores significant positive momentum in the aerospace sector.

Catalyst Watch for Marll Technologies Ahead of Conference

"Number two, I've got my eyes on the tech space as well. I'm looking at shares of Marll Technologies. This is ticker MRVL. We're seeing shares up about 1.3%. This is after city opened a positive catalyst watch on the company. This is a chipmaker. This is ahead of their conference. It's a tech conference they're going to be having next month in Las Vegas. They're saying that they expect Marll and peers to highlight growing adoption of scaleup networking including co-acked optics at the CES conference which likely will help um this company Marll to win tranium 4. So, we are seeing a bit of a positive upswing here for the company. Shares though, down on a year-to-date basis by about 23%."

The speaker highlights a positive catalyst for Marll Technologies (MRVL) with anticipation around an upcoming tech conference in Las Vegas, suggesting that increased adoption of scaleup networking and co-acked optics could drive a turnaround. Despite a 23% drop on a year-to-date basis, the commentary points to a short-term opportunity due to industry events.

Rocket Lab Secures Landmark Contract

"So, their shares are rocketing up as much as 4%. They actually jumped 18% on Friday, closed at a record high, $70.52. The reason why on Friday is because the US Space Development Agency awarded the company an agreement worth up to $85 million to provide 18 missile warning tracking defense satellites. Rocket Lab said the agreement was its biggest single contract to date. And then also came the news that it successfully launched its 21st electron rocket of the year. Their shares have been skyrocketing on this news."

Rocket Lab (RKLB) received its largest contract to date with an $85 million agreement from the US Space Development Agency, which helped propel an 18% jump and a record high close. This company-specific commentary underlines strong near-term catalysts and bullish momentum for the space launch technology company.

Mining Stocks Rally Driven by Commodity Highs – Focus on BHP

"Indeed. Yes. So, mining stocks are really gaining from this uh rally in commodities that we're seeing. So, gold, silver, copper, all hitting record highs. You know, copper's approaching $12,000 um a ton. Um and and mining stocks are are gaining on the back of this, particularly those with quite significant exposure to copper. So the likes of in London, BHP, Riotinto, Anglo-American, all higher on the back of this. And if you look at the Footsie 100, you know, mining stocks as a whole are leading the index."

The speaker underscores that mining stocks, notably BHP, are benefitting from a strong commodity rally with record highs in metals like copper driving momentum, positioning these stocks as leaders on the Footsie 100.

Harbor Energy Diversifies with LLOG Acquisition

"Harbor Energy, traditionally focused on the North Sea, is diversifying its portfolio by acquiring LLOG Exploration for 3.2 billion dollars. This deal gives Harbor exposure to the Gulf of Mexico, following previous acquisitions in South America and Africa. Despite its shares being down 22% this year, this strategic move could boost its market presence as domestic fields go into decline and windfall taxes loom."

Harbor Energy is expanding its geographic focus by acquiring LLOG Exploration for 3.2 billion dollars to gain exposure in the Gulf of Mexico. This diversification move, coupled with previous acquisitions abroad, aims to counteract domestic declines and tax pressures, potentially positioning the company for a turnaround despite a 22% drop in share price this year.

Bullion Gold Rally Boosts Mining Sector

"There's been a ferocious rally in bullion gold prices, with gold trading above 4,400 an ounce and setting a record high. This surge is boosting mining stocks, with companies like Snello up and a game run of 436% this year. Additionally, rising geopolitical tensions in Venezuela and Ukraine are strengthening gold's safe haven appeal."

A robust rally in gold prices, now above 4,400 an ounce, is driving significant gains in mining stocks, with some stocks up by as much as 436% year-to-date. Geopolitical tensions are adding to gold's appeal as a safe haven, further boosting the overall mining sector.

Telecom Italia Simplifies Capital Structure

"Telecom Italia is calling time on their capital structure by eliminating the savings share class which has been used since the 1970s. The company recently won a court case against the Italian government, netting a 1 billion euro windfall, and now aims to boost stock liquidity and lower administrative costs. The change will be put to shareholders at the end of January."

Telecom Italia plans to simplify its capital structure by eliminating the savings share class, leveraging a recent 1 billion euro court win. This move is expected to increase liquidity and reduce administrative costs, with shareholder approval expected at the end of January.

Bullish Commentary on Rivian's Momentum

"Rivian kind of came in and surprised me this week. wasn't doing so well last week after it had uh this AI and autonomy investor day. Traders were I think they needed a bit of time to metabolize what they'd been told. Um but now they're full sending on Rivian. Rivian up 22% this week. That's the best week since Janu uh July of last year and closed at a a two-year high. And Wedbush's Dan Ives boosted his price target from 25 from $16 to $25 today. And this really comes off the back of what they said at this autonomy day last week. This this push into building their own AI chips and getting full self-driving out. And also traders have really really been looking forward to Rivian dropping the R2. It's their midsize SUV. It's supposed to be a quote unquote cheaper model and they think it could really change the game. There's not really a lot of cheaper EVs in the market."

The speaker highlights an unexpected rebound in Rivian's stock performance, noting a 22% week increase and a record two-year high. He emphasizes catalyst points including an updated price target from Wedbush's Dan Ives, the company's push into developing its own AI chips, and anticipation around its upcoming R2 midsize SUV, positioning the company favorably in a competitive EV market.

White Fiber's AI Data Center Expansion Commentary

"A small market cap about $617 million. Ticker is WYFI, White Fiber. Uh, it was spun out this year from its parent company, Bit Digital, which is a crypto firm, which spun it off to focus on AI infrastructure. White Fiber provides AI data centers with what's known as biological white fibers for quick fi uh quick power and fast computing needed by AI and machine learning tasks. Um and what happened is some news today announced a 10-year 40 megawatt colllocation agreement between its subsidiary nom uh data centers and nscale global holdings. There's a lot of stuff in here but basically a new megawatt um data center. What's interesting is it takes kind of existing facilities and makes it ready for high performance data center compute if you will that's needed for AI machine learning and all that good stuff. So I just like to throw that out. It's a stock that is down about 5% though since its IPO back in August."

The speaker outlines key details regarding White Fiber (WYFI), a small cap company focused on AI infrastructure. The company, spun off from Bit Digital, recently announced a 10-year, 40 megawatt colocation agreement to upgrade existing facilities for high performance AI computing. Though the stock is down 5% since its IPO, the contract and its strategic positioning in AI data center services are highlighted as potential catalysts.

Biomarin surges on acquisition move to bolster rare disease pipeline

"Yes, this stock is up in a big way. It's up 17%, biggest jump since November 16. Biomarin Pharm Pharmaceutical BMRN. They agreed to buy Amicus Therapeutics, which is a biotech company that will help the company expand its treatments for rare diseases. So, they specialize in rare disease. And that stock, Amicus, is also up in a pretty big way with some double digit gain. Deal news in the pharma industry is clearly driving the move."

Biomarin (BMRN) experienced a sharp 17% jump following news of its acquisition of Amicus Therapeutics. The move is seen as a strategic play to expand its rare disease treatment portfolio, with the market responding positively to the deal news.

Nike faces ongoing weakness amid disappointing Q3 guidance

"That's momentum to the upside, little momentum to the downside, unfortunately, for Nike today. This is the fourth straight day that the sportswear retailer is dropping. It's lost over 10 billion in market cap just today. Biggest drop since April. Ticker NK. We all know this company well. It's down about 11% right now. The third quarter guidance disappointed investors as they warned that sales will decline this quarter amid weakness in China and with the Converse brand."

Nike is experiencing significant pressure with its stock declining for the fourth straight day, driven in part by disappointing Q3 guidance and sales concerns in key markets. The cumulative drop and investor disappointment signal continued headwinds in the near term.

Oracle poised for cloud revenue boost amid TikTok JV news

"Oracle, ticker OCL, it's up about 7%. It's still down 15% on the month, but we did recently get news that Tik Tok is said it's being bought by a group of buyers led by the software company Oracle. And the Tik Tok CEO told employees that Bite Dance, their parent company, signed binding agreements to create a joint venture majority owned by American investors, including Oracle. This will drive revenue for Oracle's cloud infrastructure business."

The report highlights Oracle's recent positive developments, including its role in a TikTok joint venture and an upcoming data center project with Open AI, suggesting a favorable impact on its cloud revenue. Despite regulatory uncertainties, the market reaction and analyst commentary indicate potential upside momentum.

KB Home Struggles in a Challenging Housing Market

"KB Home, you know, I have to always hit my real estate sector. We're looking at shares of KB Home. This is ticker KBH. We did get uh results out of LAR yesterday. KB Home is one of its peers. We're looking at the home building industry. They did post fourth quarter profit that missed expectations. The midpoint of that outlook range for fiscal 2026. Housing revenue also did fall short of expectations. So you are seeing the stock taking quite a breather down more than 8% right now. And it's been a pretty rough year for them as well down about 12%. Really just still seeing a locked housing market. Rates still remain high and there's a lot of pressures when you think about tariffs when it wastes over materials and all those things. So we really got to see whether or not these home builders are really able to turn it around."

The KB Home commentary focuses on the real estate firm's disappointing earnings, missed revenue expectations, and broader challenges in the housing sector, citing a locked market and high material costs as ongoing issues.

FedEx Faces Turnaround Challenge Amid Mixed Earnings

"Speaking of comeback stories, you're tracking another one that is waiting for a turnaround to take hold. We're looking at shares of FedEx. This is ticker FDX. Shares are down more than 1% right now. It did raise the low end of its profit outlook for this year and it reported earnings that topped expectations. Uh this of course was really helped by volume and pricing gains in the US. But, you know, we are seeing some weakness, especially as investors are trying to see whether or not the CEO's plan will really map out. They're seeing a string of cost headwinds, including the grounding of its MD11 plane. So, that's really weighing on sentiment today in the trade."

The FedEx commentary balances a positive earnings beat and improved profit outlook with significant operational headwinds, including cost pressures and uncertainty over the CEO's turnaround plan.

Negative Outlook for Nike Due to Earnings Disappointment

"I'm looking at shares of Nike. That's ticker NK. This was an earnings report that we received last night. We are seeing shares lower, down about 9% right now as we speak. This is after the company's really warning that sales would decline this quarter. They're talking about weakness both in China and its Converse brand. I completely forgot they own Converse."

The commentary highlights Nike's disappointing earnings report with sharp declines in share price driven by forecasts of lower sales, particularly impacted by weak performance in China and its Converse brand.

Oracle's Strategic TikTok Deal a Long-Term Upside Catalyst

"And then you look and you're like, oh, wait, ticktock. Oh, okay. So that was like the big push. What's the what's Oracle? Oracle is a leading group of investors involved in this joint venture to take control. Because remember, Bytedance, a company that owns, you know, behind Tick Tock, they've been under pressure from the White House because they want to split because its Chinese owner, Bytedance. And so now Oracle has kind of leading this group and it's expected to close January 22nd. This is a nice win for Oracle, some upside optionality over the long term."

The speaker highlights Oracle's leading role in a joint venture aimed at taking control of TikTok amid geopolitical pressure on Bytedance. The memo circulated to employees, along with participation from Silver Lake and MGM, is cited as a strategic move providing long-term upside despite near-term financing concerns.

Oracle's TikTok Deal as a Catalyst for Upside Optionality

"Um, Oracle, there was all this talk about, oh my AI, AI, are they going to live up to it? Oracle talked and that's what I thought cuz I heard Oracle share up 5%. What's going on? And then you look and you're like, 'Oh, wait. Tik Tok.' Okay, so that was like the big push. Oracle is a leading group of investors involved in this joint venture to take control because Bite Dance, the owner of TikTok, has been under pressure from the White House. Evercore ISI has an outperform call on Oracle, noting that while financing needs for its AI infrastructure remain a debate in the near term, this is a nice win for Oracle with some upside optionality over the long term."

Oracle is being spotlighted for its emerging role in the TikTok joint venture, seen as a strategic move amid regulatory pressures on Bite Dance. The commentary suggests a bullish sentiment, reinforced by an outperform rating from Evercore ISI, with the deal potentially unlocking upside optionality, despite near-term financing debates related to its AI infrastructure.

FedEx Faces Cost Headwinds Despite Raised Profit Outlook

"FedEx. Uh, it seemed like good news right from the start. Um FDX is ticker raised the low end of its profit outlook for the year, reported earnings topped Wall Street estimates but it just wasn't enough. Investors had these high expectations. It's been suffering from a lot of cost headwinds. You had the grounding of the MD11 planes and they said they expect a $600 million hit to adjusted earnings in the second half because of that but also because of weakness in the less than truckload freight market. They've been also affected by the trade tariff policies and more competition, with Amazon now handling much of the delivery logistics."

FedEx's update shows mixed signals. While the company raised the low end of its profit outlook and beat earnings estimates, significant cost headwinds such as the MD11 grounding and market weaknesses, compounded by rising competition from Amazon, continue to pose challenges going into the second half of the year.

Weak Nike Outlook Amid Declining Sales and Brand Shifts

"I want to start with Nike. Uh ticker NK, their shares have been down as much as 11%. So, basically, they warned that sales will decline this quarter. They talked about weakness in China, but they also talked about weakness in their Converse brand. Converse sales plunged 30% in the latest quarter. After two straight periods of growth you have them expecting revenue to be down in the low single digits in the three months that started in se December 1st."

Nike's commentary reveals a bearish outlook driven by an expected decline in sales this quarter, particularly due to underperforming Converse sales and a loss of brand appeal in key markets such as China. The company anticipates low single-digit revenue declines after consecutive growth periods, raising concerns for near-term performance.

Biomarin's Deal Sparks 17% Jump

"Finally, a Biomarin company, Biomarin, ticker BMRN. It's up 17% - the biggest jump since November 2016 on deal news. They agreed to buy Amicus Therapeutics for about $4.8 billion. And this is a company that has treatments for rare diseases, so investors are taking this as now Biomarin is going to be able to expand its portfolio of treatments. It has pricing power for these rare diseases."

Biomarin shares surged 17% following the announcement of its $4.8 billion acquisition of Amicus Therapeutics, with investors expecting expanded treatment portfolios and strengthened pricing power in the rare disease market.

FedEx Turnaround Faces Mixed Earnings

"This is another turnaround story FedEx because their CEO is looking to turn around the business here and push FedEx ground and air freight networks together and slash costs. The latest earnings giving us maybe a mixed picture on how well that's going at least in the near-term. The stock is down about 2% right now, and it was down as much as 5.6% - the biggest intraday drop since June. They did upgrade their fuel targets but to a lower magnitude than the second quarter earnings beat, and then they raised the low end of the profit outlook. But the company also said they expect a $600 million hit to adjusted earnings due to higher costs from the grounding of some of their MD11s."

FedEx is undergoing a turnaround effort with initiatives to integrate its freight networks and slash costs, yet mixed earnings and a significant $600 million earnings hit from grounded MD11s suggest near-term caution.

Nike Q3 Guidance Disappoints

"Okay, so I'm looking at shares of Nike, ticker NK. They're down about 10% right now. Reported earnings on Thursday. Their third quarter guidance disappointed investors. It wasn't that bad, but they expect third quarter sales to be down low single digits, gross margins to shrink by roughly 2 percentage points due to tariffs. Can't believe we're still talking about tariffs, but they are still something that is absolutely weighing on companies here. The company also reported weak sales in China and weak sales in the Converse brand, which anecdotally feels right."

Nike reported disappointing Q3 guidance with weak sales and margin pressures driven by tariffs and lower sales in China and Converse, prompting a price target reduction from 70 to 65.

Oracle Boosts Pre-Market with TikTok US Stake

"Oracle shares are higher by close to 5% in pre-market trade, rising on the news that it will own 15% of Tik Tok US. Now, Tik Tok unveiled a long delayed plan to separate from its Chinese parent, Bite Dance. They've signed binding agreements to create a US joint venture of a majority owned by American investors. Oracle being the lead, Silverlake and MGX are also taking part. They will take a combined 50% stake in Tik Tok US. Now this joint v venture will operate as an independent entity that will control the data protection, the content moderation, the algorithm, all of the security that the US wanted uh in their own hands instead of in on Chinese ground."

Oracle is experiencing a positive pre-market reaction, rising about 5% as it leads a strategic joint venture to acquire a significant stake in TikTok US, a move that could enhance its competitive positioning in data security and content moderation.

Nike Q Decline Amid China Weakness

"Nike shares are down some 10% in pre-market trade. This comes after their results after the bell. They warned that sales will be declining this quarter amid persistent weakness in China, which is a surprising turn of events after two straight periods of sales growth for Nike. They also said that their Converse brand was another weak point. Sales plunged 30% in the latest quarter. The CEO characterized the company's rebound as still in the middle innings."

Nike is facing significant challenges as pre-market shares drop 10% following disappointing quarterly results, with steep declines in both overall sales in China and in its Converse brand.

WH Smith Under Regulatory Pressure Amid Investigation

"So WH Smith is facing a probe. So WH Smith is having a real tough time at the moment. We remember of course the accounting error from a few months back where it revealed that it had overstated its result in the North American business by 30 million pounds. And since then that has triggered a bunch of setbacks for the company. We've seen shares plunging, they've had to delay their results twice, they've had to cut their outlook twice as well, and the CEO resigned. And today there's obviously yet another setback with the financial regulator in the UK, the FCA, opening an investigation into the company. And the FCA can take enforcement actions when companies have misleading public announcements."

WH Smith is currently facing significant setbacks including an FCA investigation, dividend cuts, and delayed results following an earlier accounting error. These issues, combined with management upheaval, have led to a steep decline in share price and raised serious concerns about the company's credibility.

Puma Faces Headwinds as Nike Sales Weaken in China

"So what's happening with Nike over in the US is not good news for Puma essentially. So Nike has warned that sales would be much weaker for this quarter because of lower demand for its Converse brand and also weak sales in China. So this doesn't bode very well for Puma because they also have a huge market in China. And this seems like there does there's no recovery yet in consumer sentiment in that country with customers continuing to kind of cut back on that discretionary spending. And Nike is more exposed to that than brands like Adidas or Ant Sports for example."

The commentary warns that Nike's weak sales, particularly in China, could negatively impact Puma given its significant exposure in that market. It highlights recurring issues with product launches and capturing consumer interest, suggesting further share declines.

Renault on the Road to Recovery After Rating Upgrade

"So Renault has won back its investment grade status from S&P. So S&P has said that Renault had managed to really refresh its product lineup and broaden its presence outside of Europe. And so those two things should really help with revenue growth and with volumes over the next couple of years. And this is really a vote of confidence for the new CEO who started just over the summer. Um he's been very careful with costs. That's been a big part of his strategy."

Renault's rating upgrade by S&P is highlighted as a strong catalyst for recovery, driven by a refreshed product lineup and expansion outside Europe. The commentary emphasizes the new CEO's cost discipline and strategic market focus, suggesting potential revenue and volume growth over the next couple of years.

Ipsen's Experimental Drug Fails in Mid-Stage Trial

"They are so just just a quick one on them. Uh they uh their mid-stage trial for one of their experimental drugs uh failed essentially. So this was for an oral drug for a very rare bone disease and it didn't meet the primary end points. The study had gone on for 5 years um and it's now going to be closed. Analysts are saying the hopes are dashed for developing this treatment. It was one of the few tools Ipsen had to offset a lot of competition, highlighting the need for M&A to boost growth. So, as you say, shares are falling quite heavily."

Ipsen's mid-stage trial for an experimental oral drug intended for a rare bone disease has failed to meet its primary endpoints after a 5-year study, dashing development hopes. This outcome puts pressure on the company to pursue M&A strategies to counteract competitive challenges, with shares falling significantly.

BBVA Announces Largest Ever Share Buyback

"Yeah. Slight slightly different story there. Bit more of a positive one. So they're announcing just under4 billion euros buyback. Yeah. Largest ever as you say. Um that's going to be in two stages and run for about a year about 12 months. So the first stage will start on Monday."

BBVA has unveiled its largest ever share buyback program, valued at just under 4 billion euros and set to unfold in two stages over approximately 12 months. This initiative follows their failed bid for Sabadel and is seen as a move to restore confidence.

WH Smith Under FCA Probe and Dividend Cut Weighs on Stock

"So, WHM have confirmed this morning that they're under investigation by the FCA. So, that's obviously the financial regulator um here in London. They had a probe that um that Deote uh implemented in November and found a lack of oversight for Joe B. Smith which led to the CEO resigning. The stock has slumped and, well year to date, they're down over about 40% with added losses today, possibly heading for its worst year on record."

WH Smith is under FCA investigation amid an accounting-era probe and has cut dividends for the first time since the pandemic, with its stock down over 40% year-to-date. These developments raise significant concerns about the company's credibility and outlook.

FedEx Shows Resilience with Improved Profit Guidance and Cost Reductions

"FedEx opposite story. FedEx uh shares last I checked were up 2 and a.5% about in the post market and FedEx narrowed its fullear EPS guidance to the upside and also posted a quarterly beat on profit and that really comes from the fact that demand is improving."

The commentary highlights that FedEx is benefiting from improved demand, better EPS guidance, and effective cost-cutting measures, contributing to its post-market gain. It underscores the company's ability to navigate headwinds and suggests a positive near-term outlook.